├── DESCRIPTION ├── LICENSE ├── NAMESPACE ├── NEWS ├── R ├── data-demo.R ├── data.R ├── ipd.R ├── kmdata-package.R ├── kmm.R ├── plot.R ├── utils-internal.R ├── utils.R └── zzz.R ├── README.md ├── data ├── ACT1_2A.rda ├── ACT1_3A.rda ├── ACT2_2A.rda ├── ACT2_2B.rda ├── ACT2_2C.rda ├── ACT2_2D.rda ├── ACTSCC_2A.rda ├── AIO0207(a)_3B.rda ├── AIO0207(a)_3C.rda ├── AIO0207(b)_3B.rda ├── AIO0207(b)_3C.rda ├── ALTTO(a)_2A.rda ├── ALTTO(a)_2B.rda ├── ALTTO(b)_2A.rda ├── ALTTO(b)_2B.rda ├── ALTTO(c)_2A.rda ├── ALTTO(c)_2B.rda ├── AMAROS_2A.rda ├── AMAROS_2B.rda ├── ASPECCT_2A.rda ├── ASPECCT_3A.rda ├── ATTENTION_2A.rda ├── ATTENTION_2B.rda ├── AURA3_1A.rda ├── AZURE_2A.rda ├── AZURE_4.rda ├── BEACON_2A.rda ├── BEACON_2B.rda ├── BEBYP_1.rda ├── BEBYP_3.rda ├── BEYOND_2A.rda ├── BEYOND_3A.rda ├── BOLERO1_2B.rda ├── BOLERO2_1.rda ├── BOLERO3_2.rda ├── BREC_2A.rda ├── BREC_2C.rda ├── CA097375_2.rda ├── CA097375_3.rda ├── CA184-095_2A.rda ├── CA184-095_3.rda ├── CA184043_2A.rda ├── CA184043_4.rda ├── CAIRO3_2A.rda ├── CAIRO3_2B.rda ├── CAIRO3_2D.rda ├── CALGB40502_2A.rda ├── CALGB40502_2B.rda ├── CALGB40502_2C.rda ├── CALGB40502_2D.rda ├── CALGB40503_2A.rda ├── CALGB40503_2B.rda ├── CALGB90202_2B.rda ├── CALGB90202_2C.rda ├── CBCSG006_2A.rda ├── CBCSG006_2B.rda ├── CEREBEL_2A.rda ├── CEREBEL_2B.rda ├── CHHiP(a)_2A.rda ├── CHHiP(a)_2B.rda ├── CHHiP(b)_2A.rda ├── CHHiP(b)_2B.rda ├── CLEOPATRA_2A.rda ├── CLEOPATRA_3A.rda ├── COMET1_2A.rda ├── COMET1_2B.rda ├── CONCEPT_1A.rda ├── CONCUR_2A.rda ├── CONCUR_3A.rda ├── COUAA202_2.rda ├── Checkmate017_1.rda ├── Checkmate017_2B.rda ├── Checkmate057_1A.rda ├── Checkmate057_1C.rda ├── Chronicle_2A.rda ├── Chronicle_2B.rda ├── DART0105_2A.rda ├── DART0105_2B.rda ├── DELTA_2A.rda ├── DELTA_2B.rda ├── E1199(a)_2A.rda ├── E1199(a)_2C.rda ├── E1199(b)_2A.rda ├── E1199(b)_2C.rda ├── E1199(c)_2A.rda ├── E1199(c)_2C.rda ├── EAGLE_1.rda ├── ELDA_1A.rda ├── ELDA_1B.rda ├── ELM-PC4_2A.rda ├── ELM-PC4_3A.rda ├── ELM-PC5_2A.rda ├── ELM-PC5_2B.rda ├── ENESTg1_2A.rda ├── ENESTg1_2B.rda ├── ENSURE_2A.rda ├── ENSURE_3A.rda ├── EORTC22881_2.rda ├── ERCC1_2A.rda ├── ERCC1_2B.rda ├── ERCC1_2C.rda ├── ERCC1_2D.rda ├── ESPATUE_2.rda ├── ESPATUE_3.rda ├── ExteNET_2A.rda ├── FALCON_2.rda ├── FFCD2001_S1A.rda ├── FFCD2001_S1B.rda ├── FFCD2001_S1C.rda ├── FFCD2001_S1D.rda ├── FIRE3_2A.rda ├── FIRE3_2B.rda ├── GECESTRO-APBI_3.rda ├── GECESTRO-APBI_4.rda ├── GEICAM2003_2A.rda ├── GEICAM2003_2B.rda ├── GETUG12_2.rda ├── GETUG16_2.rda ├── GIM2_2A.rda ├── GIM2_2B.rda ├── GIM2_2C.rda ├── GIM2_2D.rda ├── GIM_3.rda ├── HYPRO_2A.rda ├── HYPRO_2B.rda ├── IBCSG2200_2A.rda ├── IMELDA_2A.rda ├── IMELDA_2B.rda ├── IMPRESS_2.rda ├── INSPIRE_2A.rda ├── INSPIRE_2B.rda ├── INT0142_2A.rda ├── INT0142_2B.rda ├── ITACa_2A.rda ├── ITACa_2B.rda ├── JCOG0509_2A.rda ├── JCOG0509_2B.rda ├── JCOG0605_2A.rda ├── JCOG0605_2B.rda ├── JFMC33-0502_2A.rda ├── JFMC33-0502_2B.rda ├── KEYNOTE024_1A.rda ├── KEYNOTE024_2.rda ├── LEA_2A.rda ├── LEA_2C.rda ├── LUMELung1_2A.rda ├── LUMELung1_3C.rda ├── LUXBreast1_2.rda ├── LUXBreast1_4.rda ├── LUXLung3-6_2A.rda ├── LUXLung3-6_2B.rda ├── LUXLung5_1A.rda ├── LUXLung5_1B.rda ├── LUXLung6(2)_2A.rda ├── LUXLung8_2A.rda ├── LUXLung8_3A.rda ├── MA17R_1A.rda ├── MA17R_1B.rda ├── MA31_2.rda ├── MA31_3.rda ├── MAGRIT_2A.rda ├── MAGRIT_2C.rda ├── MAINSAIL_2A.rda ├── MAINSAIL_2B.rda ├── MAPS_2A.rda ├── MAPS_2C.rda ├── MARIANNE(a)_2A.rda ├── MARIANNE(b)_2A.rda ├── MARQUEE_2A.rda ├── MARQUEE_2B.rda ├── METlung_2A.rda ├── METlung_3A.rda ├── MINDACT_2C.rda ├── MINDACT_2D.rda ├── MINDACT_2E.rda ├── MINDACT_2F.rda ├── MIROX_2A.rda ├── MIROX_2B.rda ├── MONALEESA2_1.rda ├── MRC-RT01_2A.rda ├── MRC-RT01_2C.rda ├── NCICBR26_2A.rda ├── NCICBR26_2B.rda ├── NCT00294996_1A.rda ├── NCT00294996_1B.rda ├── NCT00337103_2A.rda ├── NCT00337103_2B.rda ├── NCT00596830_2A.rda ├── NCT00596830_2B.rda ├── NCT00614393(a)_3A.rda ├── NCT00614393(a)_3B.rda ├── NCT00614393(b)_3A.rda ├── NCT00614393(b)_3B.rda ├── NCT00673049_2A.rda ├── NCT00673049_2B.rda ├── NCT00938652_2A.rda ├── NCT00938652_2C.rda ├── NCT01234311_2A.rda ├── NCT01234311_2B.rda ├── NITRO_2A.rda ├── NITRO_2B.rda ├── NO16968_2A.rda ├── NO16968_2C.rda ├── NOAH_2A.rda ├── NOAH_2B.rda ├── NSABPB35_2.rda ├── NSABPB35_3.rda ├── NSABPB40_3A.rda ├── NSABPB40_3B.rda ├── NSABPR04_3A.rda ├── NSABPR04_3B.rda ├── NSABPR04_5A.rda ├── NSABPR04_5B.rda ├── NTR1527_2.rda ├── NTR1527_4.rda ├── NeoALTTO(a)_2A.rda ├── NeoALTTO(a)_2D.rda ├── NeoALTTO(b)_2A.rda ├── NeoALTTO(b)_2D.rda ├── OMEGA_3A.rda ├── OMEGA_3B.rda ├── OPTIMAL_1.rda ├── OPTIMOX3_3A.rda ├── OPTIMOX3_3B.rda ├── PALOMA2_1A.rda ├── PALOMA3_1A.rda ├── PALOMA3_2A.rda ├── PEGASE07_2A.rda ├── PEGASE07_2B.rda ├── PETACC8_2A.rda ├── PETACC8_3A.rda ├── PREVAIL_1A.rda ├── PREVAIL_1B.rda ├── PROCLAIM_2A.rda ├── PROCLAIM_2B.rda ├── PROCTOR-SCRIPT_1A.rda ├── PROCTOR-SCRIPT_1B.rda ├── PROFILE1014_1A.rda ├── PROFILE1014_1B.rda ├── PROFILE1014_2A.rda ├── PROSE_2A.rda ├── PROSE_2B.rda ├── QUARTZ_2A.rda ├── QUASAR2_2A.rda ├── QUASAR2_2B.rda ├── R98_2.rda ├── R98_4.rda ├── RADIANT4_2A.rda ├── RADIANT4_2C.rda ├── RADIANT_2A.rda ├── RAISE_2A.rda ├── RAISE_2B.rda ├── RECOURSE_1A.rda ├── RECOURSE_2A.rda ├── REVEL_2.rda ├── REVEL_3.rda ├── ROSE_2A.rda ├── ROSE_2C.rda ├── RTOG0415_2.rda ├── RTOG0617_2A.rda ├── RTOG0617_2B.rda ├── RTOG9804_2C.rda ├── RTOG9804_2D.rda ├── SAKK4106_1.rda ├── SAKK4106_3.rda ├── SAKK_2A.rda ├── SAKK_2B.rda ├── SELECTBC_2A.rda ├── SELECTBC_2B.rda ├── SIRFLOX_3.rda ├── SMART_3.rda ├── SMX1132531_1.rda ├── SOFT_2A.rda ├── SQUIRE_2A.rda ├── SQUIRE_2B.rda ├── TANIA_2.rda ├── TCOG0701_1A.rda ├── TCOG0701_1B.rda ├── TEXT-SOFT(2)_2A.rda ├── TEXT-SOFT(2)_2D.rda ├── TH3RESA_2A.rda ├── TH3RESA_4.rda ├── TRAPEZE_1A.rda ├── TRAPEZE_1B.rda ├── TRIBE(2)_2A.rda ├── TRIBE(2)_2B.rda ├── TRIBE_2.rda ├── TROG0306_2.rda ├── TURANDOT_2B.rda ├── TURANDOT_3.rda ├── VANTAGE014_2.rda ├── VANTAGE014_4.rda ├── WJOG5108L_2A.rda ├── WJOG5108L_2B.rda ├── WJOG5208L_2A.rda ├── WJOG5208L_2B.rda ├── WSG-ARA_3.rda ├── WSGAGO_2A.rda ├── X20050181_1A.rda ├── X20050181_1B.rda ├── X20050181_2A.rda ├── X20050181_2B.rda ├── X2005B3030_2A.rda ├── X2005B3030_2B.rda ├── kmdata_demo.rda └── kmdata_key.rda ├── inst ├── docs │ └── Citations_final.xlsx └── etc │ └── init │ ├── Checkmate_067_At_Risk.csv │ └── Checkmate_067_S3A_Nivolumab.csv ├── man ├── ACT1_2A.Rd ├── ACT1_3A.Rd ├── ACT2_2A.Rd ├── ACT2_2B.Rd ├── ACT2_2C.Rd ├── ACT2_2D.Rd ├── ACTSCC_2A.Rd ├── AIO0207-open-paren-a-close-paren-_3B.Rd ├── AIO0207-open-paren-a-close-paren-_3C.Rd ├── AIO0207-open-paren-b-close-paren-_3B.Rd ├── AIO0207-open-paren-b-close-paren-_3C.Rd ├── ALTTO-open-paren-a-close-paren-_2A.Rd ├── ALTTO-open-paren-a-close-paren-_2B.Rd ├── ALTTO-open-paren-b-close-paren-_2A.Rd ├── ALTTO-open-paren-b-close-paren-_2B.Rd ├── ALTTO-open-paren-c-close-paren-_2A.Rd ├── ALTTO-open-paren-c-close-paren-_2B.Rd ├── AMAROS_2A.Rd ├── AMAROS_2B.Rd ├── ASPECCT_2A.Rd ├── ASPECCT_3A.Rd ├── ATTENTION_2A.Rd ├── ATTENTION_2B.Rd ├── AURA3_1A.Rd ├── AZURE_2A.Rd ├── AZURE_4.Rd ├── BEACON_2A.Rd ├── BEACON_2B.Rd ├── BEBYP_1.Rd ├── BEBYP_3.Rd ├── BEYOND_2A.Rd ├── BEYOND_3A.Rd ├── BOLERO1_2B.Rd ├── BOLERO2_1.Rd ├── BOLERO3_2.Rd ├── BREC_2A.Rd ├── BREC_2C.Rd ├── CA097375_2.Rd ├── CA097375_3.Rd ├── CA184-095_2A.Rd ├── CA184-095_3.Rd ├── CA184043_2A.Rd ├── CA184043_4.Rd ├── CAIRO3_2A.Rd ├── CAIRO3_2B.Rd ├── CAIRO3_2D.Rd ├── CALGB40502_2A.Rd ├── CALGB40502_2B.Rd ├── CALGB40502_2C.Rd ├── CALGB40502_2D.Rd ├── CALGB40503_2A.Rd ├── CALGB40503_2B.Rd ├── CALGB90202_2B.Rd ├── CALGB90202_2C.Rd ├── CBCSG006_2A.Rd ├── CBCSG006_2B.Rd ├── CEREBEL_2A.Rd ├── CEREBEL_2B.Rd ├── CHHiP-open-paren-a-close-paren-_2A.Rd ├── CHHiP-open-paren-a-close-paren-_2B.Rd ├── CHHiP-open-paren-b-close-paren-_2A.Rd ├── CHHiP-open-paren-b-close-paren-_2B.Rd ├── CLEOPATRA_2A.Rd ├── CLEOPATRA_3A.Rd ├── COMET1_2A.Rd ├── COMET1_2B.Rd ├── CONCEPT_1A.Rd ├── CONCUR_2A.Rd ├── CONCUR_3A.Rd ├── COUAA202_2.Rd ├── Checkmate017_1.Rd ├── Checkmate017_2B.Rd ├── Checkmate057_1A.Rd ├── Checkmate057_1C.Rd ├── Chronicle_2A.Rd ├── Chronicle_2B.Rd ├── DART0105_2A.Rd ├── DART0105_2B.Rd ├── DELTA_2A.Rd ├── DELTA_2B.Rd ├── E1199-open-paren-a-close-paren-_2A.Rd ├── E1199-open-paren-a-close-paren-_2C.Rd ├── E1199-open-paren-b-close-paren-_2A.Rd ├── E1199-open-paren-b-close-paren-_2C.Rd ├── E1199-open-paren-c-close-paren-_2A.Rd ├── E1199-open-paren-c-close-paren-_2C.Rd ├── EAGLE_1.Rd ├── ELDA_1A.Rd ├── ELDA_1B.Rd ├── ELM-PC4_2A.Rd ├── ELM-PC4_3A.Rd ├── ELM-PC5_2A.Rd ├── ELM-PC5_2B.Rd ├── ENESTg1_2A.Rd ├── ENESTg1_2B.Rd ├── ENSURE_2A.Rd ├── ENSURE_3A.Rd ├── EORTC22881_2.Rd ├── ERCC1_2A.Rd ├── ERCC1_2B.Rd ├── ERCC1_2C.Rd ├── ERCC1_2D.Rd ├── ESPATUE_2.Rd ├── ESPATUE_3.Rd ├── ExteNET_2A.Rd ├── FALCON_2.Rd ├── FFCD2001_S1A.Rd ├── FFCD2001_S1B.Rd ├── FFCD2001_S1C.Rd ├── FFCD2001_S1D.Rd ├── FIRE3_2A.Rd ├── FIRE3_2B.Rd ├── GECESTRO-APBI_3.Rd ├── GECESTRO-APBI_4.Rd ├── GEICAM2003_2A.Rd ├── GEICAM2003_2B.Rd ├── GETUG12_2.Rd ├── GETUG16_2.Rd ├── GIM2_2A.Rd ├── GIM2_2B.Rd ├── GIM2_2C.Rd ├── GIM2_2D.Rd ├── GIM_3.Rd ├── HYPRO_2A.Rd ├── HYPRO_2B.Rd ├── IBCSG2200_2A.Rd ├── IMELDA_2A.Rd ├── IMELDA_2B.Rd ├── IMPRESS_2.Rd ├── INSPIRE_2A.Rd ├── INSPIRE_2B.Rd ├── INT0142_2A.Rd ├── INT0142_2B.Rd ├── ITACa_2A.Rd ├── ITACa_2B.Rd ├── JCOG0509_2A.Rd ├── JCOG0509_2B.Rd ├── JCOG0605_2A.Rd ├── JCOG0605_2B.Rd ├── JFMC33-0502_2A.Rd ├── JFMC33-0502_2B.Rd ├── KEYNOTE024_1A.Rd ├── KEYNOTE024_2.Rd ├── LEA_2A.Rd ├── LEA_2C.Rd ├── LUMELung1_2A.Rd ├── LUMELung1_3C.Rd ├── LUXBreast1_2.Rd ├── LUXBreast1_4.Rd ├── LUXLung3-6_2A.Rd ├── LUXLung3-6_2B.Rd ├── LUXLung5_1A.Rd ├── LUXLung5_1B.Rd ├── LUXLung6-open-paren-2-close-paren-_2A.Rd ├── LUXLung8_2A.Rd ├── LUXLung8_3A.Rd ├── MA17R_1A.Rd ├── MA17R_1B.Rd ├── MA31_2.Rd ├── MA31_3.Rd ├── MAGRIT_2A.Rd ├── MAGRIT_2C.Rd ├── MAINSAIL_2A.Rd ├── MAINSAIL_2B.Rd ├── MAPS_2A.Rd ├── MAPS_2C.Rd ├── MARIANNE-open-paren-a-close-paren-_2A.Rd ├── MARIANNE-open-paren-b-close-paren-_2A.Rd ├── MARQUEE_2A.Rd ├── MARQUEE_2B.Rd ├── METlung_2A.Rd ├── METlung_3A.Rd ├── MINDACT_2C.Rd ├── MINDACT_2D.Rd ├── MINDACT_2E.Rd ├── MINDACT_2F.Rd ├── MIROX_2A.Rd ├── MIROX_2B.Rd ├── MONALEESA2_1.Rd ├── MRC-RT01_2A.Rd ├── MRC-RT01_2C.Rd ├── NCICBR26_2A.Rd ├── NCICBR26_2B.Rd ├── NCT00294996_1A.Rd ├── NCT00294996_1B.Rd ├── NCT00337103_2A.Rd ├── NCT00337103_2B.Rd ├── NCT00596830_2A.Rd ├── NCT00596830_2B.Rd ├── NCT00614393-open-paren-a-close-paren-_3A.Rd ├── NCT00614393-open-paren-a-close-paren-_3B.Rd ├── NCT00614393-open-paren-b-close-paren-_3A.Rd ├── NCT00614393-open-paren-b-close-paren-_3B.Rd ├── NCT00673049_2A.Rd ├── NCT00673049_2B.Rd ├── NCT00938652_2A.Rd ├── NCT00938652_2C.Rd ├── NCT01234311_2A.Rd ├── NCT01234311_2B.Rd ├── NITRO_2A.Rd ├── NITRO_2B.Rd ├── NO16968_2A.Rd ├── NO16968_2C.Rd ├── NOAH_2A.Rd ├── NOAH_2B.Rd ├── NSABPB35_2.Rd ├── NSABPB35_3.Rd ├── NSABPB40_3A.Rd ├── NSABPB40_3B.Rd ├── NSABPR04_3A.Rd ├── NSABPR04_3B.Rd ├── NSABPR04_5A.Rd ├── NSABPR04_5B.Rd ├── NTR1527_2.Rd ├── NTR1527_4.Rd ├── NeoALTTO-open-paren-a-close-paren-_2A.Rd ├── NeoALTTO-open-paren-a-close-paren-_2D.Rd ├── NeoALTTO-open-paren-b-close-paren-_2A.Rd ├── NeoALTTO-open-paren-b-close-paren-_2D.Rd ├── OMEGA_3A.Rd ├── OMEGA_3B.Rd ├── OPTIMAL_1.Rd ├── OPTIMOX3_3A.Rd ├── OPTIMOX3_3B.Rd ├── PALOMA2_1A.Rd ├── PALOMA3_1A.Rd ├── PALOMA3_2A.Rd ├── PEGASE07_2A.Rd ├── PEGASE07_2B.Rd ├── PETACC8_2A.Rd ├── PETACC8_3A.Rd ├── PREVAIL_1A.Rd ├── PREVAIL_1B.Rd ├── PROCLAIM_2A.Rd ├── PROCLAIM_2B.Rd ├── PROCTOR-SCRIPT_1A.Rd ├── PROCTOR-SCRIPT_1B.Rd ├── PROFILE1014_1A.Rd ├── PROFILE1014_1B.Rd ├── PROFILE1014_2A.Rd ├── PROSE_2A.Rd ├── PROSE_2B.Rd ├── QUARTZ_2A.Rd ├── QUASAR2_2A.Rd ├── QUASAR2_2B.Rd ├── R98_2.Rd ├── R98_4.Rd ├── RADIANT4_2A.Rd ├── RADIANT4_2C.Rd ├── RADIANT_2A.Rd ├── RAISE_2A.Rd ├── RAISE_2B.Rd ├── RECOURSE_1A.Rd ├── RECOURSE_2A.Rd ├── REVEL_2.Rd ├── REVEL_3.Rd ├── ROSE_2A.Rd ├── ROSE_2C.Rd ├── RTOG0415_2.Rd ├── RTOG0617_2A.Rd ├── RTOG0617_2B.Rd ├── RTOG9804_2C.Rd ├── RTOG9804_2D.Rd ├── SAKK4106_1.Rd ├── SAKK4106_3.Rd ├── SAKK_2A.Rd ├── SAKK_2B.Rd ├── SELECTBC_2A.Rd ├── SELECTBC_2B.Rd ├── SIRFLOX_3.Rd ├── SMART_3.Rd ├── SMX1132531_1.Rd ├── SOFT_2A.Rd ├── SQUIRE_2A.Rd ├── SQUIRE_2B.Rd ├── TANIA_2.Rd ├── TCOG0701_1A.Rd ├── TCOG0701_1B.Rd ├── TEXT-SOFT-open-paren-2-close-paren-_2A.Rd ├── TEXT-SOFT-open-paren-2-close-paren-_2D.Rd ├── TH3RESA_2A.Rd ├── TH3RESA_4.Rd ├── TRAPEZE_1A.Rd ├── TRAPEZE_1B.Rd ├── TRIBE-open-paren-2-close-paren-_2A.Rd ├── TRIBE-open-paren-2-close-paren-_2B.Rd ├── TRIBE_2.Rd ├── TROG0306_2.Rd ├── TURANDOT_2B.Rd ├── TURANDOT_3.Rd ├── VANTAGE014_2.Rd ├── VANTAGE014_4.Rd ├── WJOG5108L_2A.Rd ├── WJOG5108L_2B.Rd ├── WJOG5208L_2A.Rd ├── WJOG5208L_2B.Rd ├── WSG-ARA_3.Rd ├── WSGAGO_2A.Rd ├── X20050181_1A.Rd ├── X20050181_1B.Rd ├── X20050181_2A.Rd ├── X20050181_2B.Rd ├── X2005B3030_2A.Rd ├── X2005B3030_2B.Rd ├── ipd.Rd ├── kmdata-package.Rd ├── kmdata_demo.Rd ├── kmdata_key.Rd ├── kmm.Rd ├── kmm_legend.Rd ├── kmplot.Rd ├── select_kmdata.Rd └── summary.kmdata.Rd └── vignettes ├── kmdata-intro.Rmd └── kmdata-ipd.Rmd /DESCRIPTION: -------------------------------------------------------------------------------- 1 | Package: kmdata 2 | Type: Package 3 | Title: A Database of Reconstructed Individual Patient Level Data from 4 | Oncology Clinical Trials 5 | Version: 1.0.1 6 | Date: 2022-05-11 7 | Authors@R: as.person(c( 8 | "Robert Redd [aut, cre]", 9 | "Geoffrey Fell [aut]", 10 | "Rifaquat Rahman [aut]" 11 | )) 12 | Author: Robert Redd [aut, cre], Geoffrey Fell [aut], Rifaquat Rahman [aut] 13 | Maintainer: Robert Redd 14 | Description: Digitized Kaplan-Meier data. 15 | Depends: 16 | survival 17 | Imports: 18 | fdrtool, 19 | graphics, 20 | stats 21 | Suggests: 22 | knitr, 23 | readxl, 24 | testthat 25 | License: MIT + file LICENSE 26 | LazyData: yes 27 | URL: https://github.com/raredd/kmdata 28 | VignetteBuilder: knitr 29 | RoxygenNote: 7.3.2 30 | Encoding: UTF-8 31 | -------------------------------------------------------------------------------- /LICENSE: -------------------------------------------------------------------------------- 1 | YEAR: 2021 2 | COPYRIGHT HOLDER: Robert Redd 3 | -------------------------------------------------------------------------------- /NAMESPACE: -------------------------------------------------------------------------------- 1 | # Generated by roxygen2: do not edit by hand 2 | 3 | S3method(plot,kmdata) 4 | S3method(summary,kmdata) 5 | export(ipd) 6 | export(kmm) 7 | export(kmm_legend) 8 | export(kmplot) 9 | export(select_kmdata) 10 | import(survival) 11 | importFrom(fdrtool,monoreg) 12 | importFrom(graphics,axis) 13 | importFrom(graphics,box) 14 | importFrom(graphics,grconvertX) 15 | importFrom(graphics,hist) 16 | importFrom(graphics,mtext) 17 | importFrom(graphics,par) 18 | importFrom(graphics,text) 19 | importFrom(stats,as.formula) 20 | importFrom(stats,pchisq) 21 | importFrom(stats,terms) 22 | -------------------------------------------------------------------------------- /NEWS: -------------------------------------------------------------------------------- 1 | kmdata 1.0.1 2 | 13 may 2021 3 | -------- 4 | * add demographics by publication/therapy received 5 | 6 | kmdata 1.0.0 7 | 27 jul 2020 8 | -------- 9 | * initial release 10 | 11 | kmdata 0.0.0.9004 12 | 01 jul 2020 13 | -------- 14 | * add missing citations 15 | * add time units, missing events, tx arm labels, tx class, year, quality 16 | * add units, events to kmplot 17 | * update descriptions of kmdata_key 18 | * add intro, ipd vignettes 19 | 20 | kmdata 0.0.0.9003 21 | 17 feb 2020 22 | -------- 23 | * updates, bug fixes 24 | 25 | kmdata 0.0.0.9002 26 | 17 feb 2020 27 | -------- 28 | * add validation, deviance measures 29 | * add select_kmdata, kmdata_key 30 | * updated manuscript 31 | * updates, additional features of kmplot 32 | * expand docs and examples 33 | 34 | kmdata 0.0.0.9001 35 | 01 dec 2019 36 | -------- 37 | * digi - fix time=0 bug 38 | * ipd_ - alternatives for case of atrisk=0/KMhat=0/d=NaN 39 | * fix errors in delta data example 40 | 41 | kmdata 0.0.0.9000 42 | 14 nov 2019 43 | -------- 44 | * initial build 45 | -------------------------------------------------------------------------------- /R/zzz.R: -------------------------------------------------------------------------------- 1 | ### internals 2 | 3 | 4 | ## binding notes 5 | if (getRversion() >= '2.15.1') { 6 | utils::globalVariables(NULL) 7 | } 8 | -------------------------------------------------------------------------------- /data/ACT1_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ACT1_2A.rda -------------------------------------------------------------------------------- /data/ACT1_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ACT1_3A.rda -------------------------------------------------------------------------------- /data/ACT2_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ACT2_2A.rda -------------------------------------------------------------------------------- /data/ACT2_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ACT2_2B.rda -------------------------------------------------------------------------------- /data/ACT2_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ACT2_2C.rda -------------------------------------------------------------------------------- /data/ACT2_2D.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ACT2_2D.rda -------------------------------------------------------------------------------- /data/ACTSCC_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ACTSCC_2A.rda -------------------------------------------------------------------------------- /data/AIO0207(a)_3B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/AIO0207(a)_3B.rda -------------------------------------------------------------------------------- /data/AIO0207(a)_3C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/AIO0207(a)_3C.rda -------------------------------------------------------------------------------- /data/AIO0207(b)_3B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/AIO0207(b)_3B.rda -------------------------------------------------------------------------------- /data/AIO0207(b)_3C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/AIO0207(b)_3C.rda -------------------------------------------------------------------------------- /data/ALTTO(a)_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ALTTO(a)_2A.rda -------------------------------------------------------------------------------- /data/ALTTO(a)_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ALTTO(a)_2B.rda -------------------------------------------------------------------------------- /data/ALTTO(b)_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ALTTO(b)_2A.rda -------------------------------------------------------------------------------- /data/ALTTO(b)_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ALTTO(b)_2B.rda -------------------------------------------------------------------------------- /data/ALTTO(c)_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ALTTO(c)_2A.rda -------------------------------------------------------------------------------- /data/ALTTO(c)_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ALTTO(c)_2B.rda -------------------------------------------------------------------------------- /data/AMAROS_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/AMAROS_2A.rda -------------------------------------------------------------------------------- /data/AMAROS_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/AMAROS_2B.rda -------------------------------------------------------------------------------- /data/ASPECCT_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ASPECCT_2A.rda -------------------------------------------------------------------------------- /data/ASPECCT_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ASPECCT_3A.rda -------------------------------------------------------------------------------- /data/ATTENTION_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ATTENTION_2A.rda -------------------------------------------------------------------------------- /data/ATTENTION_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ATTENTION_2B.rda -------------------------------------------------------------------------------- /data/AURA3_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/AURA3_1A.rda -------------------------------------------------------------------------------- /data/AZURE_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/AZURE_2A.rda -------------------------------------------------------------------------------- /data/AZURE_4.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/AZURE_4.rda -------------------------------------------------------------------------------- /data/BEACON_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/BEACON_2A.rda -------------------------------------------------------------------------------- /data/BEACON_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/BEACON_2B.rda -------------------------------------------------------------------------------- /data/BEBYP_1.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/BEBYP_1.rda -------------------------------------------------------------------------------- /data/BEBYP_3.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/BEBYP_3.rda -------------------------------------------------------------------------------- /data/BEYOND_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/BEYOND_2A.rda -------------------------------------------------------------------------------- /data/BEYOND_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/BEYOND_3A.rda -------------------------------------------------------------------------------- /data/BOLERO1_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/BOLERO1_2B.rda -------------------------------------------------------------------------------- /data/BOLERO2_1.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/BOLERO2_1.rda -------------------------------------------------------------------------------- /data/BOLERO3_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/BOLERO3_2.rda -------------------------------------------------------------------------------- /data/BREC_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/BREC_2A.rda -------------------------------------------------------------------------------- /data/BREC_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/BREC_2C.rda -------------------------------------------------------------------------------- /data/CA097375_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CA097375_2.rda -------------------------------------------------------------------------------- /data/CA097375_3.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CA097375_3.rda -------------------------------------------------------------------------------- /data/CA184-095_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CA184-095_2A.rda -------------------------------------------------------------------------------- /data/CA184-095_3.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CA184-095_3.rda -------------------------------------------------------------------------------- /data/CA184043_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CA184043_2A.rda -------------------------------------------------------------------------------- /data/CA184043_4.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CA184043_4.rda -------------------------------------------------------------------------------- /data/CAIRO3_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CAIRO3_2A.rda -------------------------------------------------------------------------------- /data/CAIRO3_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CAIRO3_2B.rda -------------------------------------------------------------------------------- /data/CAIRO3_2D.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CAIRO3_2D.rda -------------------------------------------------------------------------------- /data/CALGB40502_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CALGB40502_2A.rda -------------------------------------------------------------------------------- /data/CALGB40502_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CALGB40502_2B.rda -------------------------------------------------------------------------------- /data/CALGB40502_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CALGB40502_2C.rda -------------------------------------------------------------------------------- /data/CALGB40502_2D.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CALGB40502_2D.rda -------------------------------------------------------------------------------- /data/CALGB40503_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CALGB40503_2A.rda -------------------------------------------------------------------------------- /data/CALGB40503_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CALGB40503_2B.rda -------------------------------------------------------------------------------- /data/CALGB90202_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CALGB90202_2B.rda -------------------------------------------------------------------------------- /data/CALGB90202_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CALGB90202_2C.rda -------------------------------------------------------------------------------- /data/CBCSG006_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CBCSG006_2A.rda -------------------------------------------------------------------------------- /data/CBCSG006_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CBCSG006_2B.rda -------------------------------------------------------------------------------- /data/CEREBEL_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CEREBEL_2A.rda -------------------------------------------------------------------------------- /data/CEREBEL_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CEREBEL_2B.rda -------------------------------------------------------------------------------- /data/CHHiP(a)_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CHHiP(a)_2A.rda -------------------------------------------------------------------------------- /data/CHHiP(a)_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CHHiP(a)_2B.rda -------------------------------------------------------------------------------- /data/CHHiP(b)_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CHHiP(b)_2A.rda -------------------------------------------------------------------------------- /data/CHHiP(b)_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CHHiP(b)_2B.rda -------------------------------------------------------------------------------- /data/CLEOPATRA_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CLEOPATRA_2A.rda -------------------------------------------------------------------------------- /data/CLEOPATRA_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CLEOPATRA_3A.rda -------------------------------------------------------------------------------- /data/COMET1_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/COMET1_2A.rda -------------------------------------------------------------------------------- /data/COMET1_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/COMET1_2B.rda -------------------------------------------------------------------------------- /data/CONCEPT_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CONCEPT_1A.rda -------------------------------------------------------------------------------- /data/CONCUR_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CONCUR_2A.rda -------------------------------------------------------------------------------- /data/CONCUR_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/CONCUR_3A.rda -------------------------------------------------------------------------------- /data/COUAA202_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/COUAA202_2.rda -------------------------------------------------------------------------------- /data/Checkmate017_1.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/Checkmate017_1.rda -------------------------------------------------------------------------------- /data/Checkmate017_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/Checkmate017_2B.rda -------------------------------------------------------------------------------- /data/Checkmate057_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/Checkmate057_1A.rda -------------------------------------------------------------------------------- /data/Checkmate057_1C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/Checkmate057_1C.rda -------------------------------------------------------------------------------- /data/Chronicle_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/Chronicle_2A.rda -------------------------------------------------------------------------------- /data/Chronicle_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/Chronicle_2B.rda -------------------------------------------------------------------------------- /data/DART0105_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/DART0105_2A.rda -------------------------------------------------------------------------------- /data/DART0105_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/DART0105_2B.rda -------------------------------------------------------------------------------- /data/DELTA_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/DELTA_2A.rda -------------------------------------------------------------------------------- /data/DELTA_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/DELTA_2B.rda -------------------------------------------------------------------------------- /data/E1199(a)_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/E1199(a)_2A.rda -------------------------------------------------------------------------------- /data/E1199(a)_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/E1199(a)_2C.rda -------------------------------------------------------------------------------- /data/E1199(b)_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/E1199(b)_2A.rda -------------------------------------------------------------------------------- /data/E1199(b)_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/E1199(b)_2C.rda -------------------------------------------------------------------------------- /data/E1199(c)_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/E1199(c)_2A.rda -------------------------------------------------------------------------------- /data/E1199(c)_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/E1199(c)_2C.rda -------------------------------------------------------------------------------- /data/EAGLE_1.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/EAGLE_1.rda -------------------------------------------------------------------------------- /data/ELDA_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ELDA_1A.rda -------------------------------------------------------------------------------- /data/ELDA_1B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ELDA_1B.rda -------------------------------------------------------------------------------- /data/ELM-PC4_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ELM-PC4_2A.rda -------------------------------------------------------------------------------- /data/ELM-PC4_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ELM-PC4_3A.rda -------------------------------------------------------------------------------- /data/ELM-PC5_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ELM-PC5_2A.rda -------------------------------------------------------------------------------- /data/ELM-PC5_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ELM-PC5_2B.rda -------------------------------------------------------------------------------- /data/ENESTg1_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ENESTg1_2A.rda -------------------------------------------------------------------------------- /data/ENESTg1_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ENESTg1_2B.rda -------------------------------------------------------------------------------- /data/ENSURE_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ENSURE_2A.rda -------------------------------------------------------------------------------- /data/ENSURE_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ENSURE_3A.rda -------------------------------------------------------------------------------- /data/EORTC22881_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/EORTC22881_2.rda -------------------------------------------------------------------------------- /data/ERCC1_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ERCC1_2A.rda -------------------------------------------------------------------------------- /data/ERCC1_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ERCC1_2B.rda -------------------------------------------------------------------------------- /data/ERCC1_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ERCC1_2C.rda -------------------------------------------------------------------------------- /data/ERCC1_2D.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ERCC1_2D.rda -------------------------------------------------------------------------------- /data/ESPATUE_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ESPATUE_2.rda -------------------------------------------------------------------------------- /data/ESPATUE_3.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ESPATUE_3.rda -------------------------------------------------------------------------------- /data/ExteNET_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ExteNET_2A.rda -------------------------------------------------------------------------------- /data/FALCON_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/FALCON_2.rda -------------------------------------------------------------------------------- /data/FFCD2001_S1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/FFCD2001_S1A.rda -------------------------------------------------------------------------------- /data/FFCD2001_S1B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/FFCD2001_S1B.rda -------------------------------------------------------------------------------- /data/FFCD2001_S1C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/FFCD2001_S1C.rda -------------------------------------------------------------------------------- /data/FFCD2001_S1D.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/FFCD2001_S1D.rda -------------------------------------------------------------------------------- /data/FIRE3_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/FIRE3_2A.rda -------------------------------------------------------------------------------- /data/FIRE3_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/FIRE3_2B.rda -------------------------------------------------------------------------------- /data/GECESTRO-APBI_3.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/GECESTRO-APBI_3.rda -------------------------------------------------------------------------------- /data/GECESTRO-APBI_4.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/GECESTRO-APBI_4.rda -------------------------------------------------------------------------------- /data/GEICAM2003_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/GEICAM2003_2A.rda -------------------------------------------------------------------------------- /data/GEICAM2003_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/GEICAM2003_2B.rda -------------------------------------------------------------------------------- /data/GETUG12_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/GETUG12_2.rda -------------------------------------------------------------------------------- /data/GETUG16_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/GETUG16_2.rda -------------------------------------------------------------------------------- /data/GIM2_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/GIM2_2A.rda -------------------------------------------------------------------------------- /data/GIM2_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/GIM2_2B.rda -------------------------------------------------------------------------------- /data/GIM2_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/GIM2_2C.rda -------------------------------------------------------------------------------- /data/GIM2_2D.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/GIM2_2D.rda -------------------------------------------------------------------------------- /data/GIM_3.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/GIM_3.rda -------------------------------------------------------------------------------- /data/HYPRO_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/HYPRO_2A.rda -------------------------------------------------------------------------------- /data/HYPRO_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/HYPRO_2B.rda -------------------------------------------------------------------------------- /data/IBCSG2200_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/IBCSG2200_2A.rda -------------------------------------------------------------------------------- /data/IMELDA_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/IMELDA_2A.rda -------------------------------------------------------------------------------- /data/IMELDA_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/IMELDA_2B.rda -------------------------------------------------------------------------------- /data/IMPRESS_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/IMPRESS_2.rda -------------------------------------------------------------------------------- /data/INSPIRE_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/INSPIRE_2A.rda -------------------------------------------------------------------------------- /data/INSPIRE_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/INSPIRE_2B.rda -------------------------------------------------------------------------------- /data/INT0142_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/INT0142_2A.rda -------------------------------------------------------------------------------- /data/INT0142_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/INT0142_2B.rda -------------------------------------------------------------------------------- /data/ITACa_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ITACa_2A.rda -------------------------------------------------------------------------------- /data/ITACa_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ITACa_2B.rda -------------------------------------------------------------------------------- /data/JCOG0509_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/JCOG0509_2A.rda -------------------------------------------------------------------------------- /data/JCOG0509_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/JCOG0509_2B.rda -------------------------------------------------------------------------------- /data/JCOG0605_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/JCOG0605_2A.rda -------------------------------------------------------------------------------- /data/JCOG0605_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/JCOG0605_2B.rda -------------------------------------------------------------------------------- /data/JFMC33-0502_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/JFMC33-0502_2A.rda -------------------------------------------------------------------------------- /data/JFMC33-0502_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/JFMC33-0502_2B.rda -------------------------------------------------------------------------------- /data/KEYNOTE024_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/KEYNOTE024_1A.rda -------------------------------------------------------------------------------- /data/KEYNOTE024_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/KEYNOTE024_2.rda -------------------------------------------------------------------------------- /data/LEA_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/LEA_2A.rda -------------------------------------------------------------------------------- /data/LEA_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/LEA_2C.rda -------------------------------------------------------------------------------- /data/LUMELung1_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/LUMELung1_2A.rda -------------------------------------------------------------------------------- /data/LUMELung1_3C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/LUMELung1_3C.rda -------------------------------------------------------------------------------- /data/LUXBreast1_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/LUXBreast1_2.rda -------------------------------------------------------------------------------- /data/LUXBreast1_4.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/LUXBreast1_4.rda -------------------------------------------------------------------------------- /data/LUXLung3-6_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/LUXLung3-6_2A.rda -------------------------------------------------------------------------------- /data/LUXLung3-6_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/LUXLung3-6_2B.rda -------------------------------------------------------------------------------- /data/LUXLung5_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/LUXLung5_1A.rda -------------------------------------------------------------------------------- /data/LUXLung5_1B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/LUXLung5_1B.rda -------------------------------------------------------------------------------- /data/LUXLung6(2)_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/LUXLung6(2)_2A.rda -------------------------------------------------------------------------------- /data/LUXLung8_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/LUXLung8_2A.rda -------------------------------------------------------------------------------- /data/LUXLung8_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/LUXLung8_3A.rda -------------------------------------------------------------------------------- /data/MA17R_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MA17R_1A.rda -------------------------------------------------------------------------------- /data/MA17R_1B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MA17R_1B.rda -------------------------------------------------------------------------------- /data/MA31_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MA31_2.rda -------------------------------------------------------------------------------- /data/MA31_3.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MA31_3.rda -------------------------------------------------------------------------------- /data/MAGRIT_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MAGRIT_2A.rda -------------------------------------------------------------------------------- /data/MAGRIT_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MAGRIT_2C.rda -------------------------------------------------------------------------------- /data/MAINSAIL_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MAINSAIL_2A.rda -------------------------------------------------------------------------------- /data/MAINSAIL_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MAINSAIL_2B.rda -------------------------------------------------------------------------------- /data/MAPS_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MAPS_2A.rda -------------------------------------------------------------------------------- /data/MAPS_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MAPS_2C.rda -------------------------------------------------------------------------------- /data/MARIANNE(a)_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MARIANNE(a)_2A.rda -------------------------------------------------------------------------------- /data/MARIANNE(b)_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MARIANNE(b)_2A.rda -------------------------------------------------------------------------------- /data/MARQUEE_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MARQUEE_2A.rda -------------------------------------------------------------------------------- /data/MARQUEE_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MARQUEE_2B.rda -------------------------------------------------------------------------------- /data/METlung_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/METlung_2A.rda -------------------------------------------------------------------------------- /data/METlung_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/METlung_3A.rda -------------------------------------------------------------------------------- /data/MINDACT_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MINDACT_2C.rda -------------------------------------------------------------------------------- /data/MINDACT_2D.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MINDACT_2D.rda -------------------------------------------------------------------------------- /data/MINDACT_2E.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MINDACT_2E.rda -------------------------------------------------------------------------------- /data/MINDACT_2F.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MINDACT_2F.rda -------------------------------------------------------------------------------- /data/MIROX_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MIROX_2A.rda -------------------------------------------------------------------------------- /data/MIROX_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MIROX_2B.rda -------------------------------------------------------------------------------- /data/MONALEESA2_1.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MONALEESA2_1.rda -------------------------------------------------------------------------------- /data/MRC-RT01_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MRC-RT01_2A.rda -------------------------------------------------------------------------------- /data/MRC-RT01_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/MRC-RT01_2C.rda -------------------------------------------------------------------------------- /data/NCICBR26_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCICBR26_2A.rda -------------------------------------------------------------------------------- /data/NCICBR26_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCICBR26_2B.rda -------------------------------------------------------------------------------- /data/NCT00294996_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT00294996_1A.rda -------------------------------------------------------------------------------- /data/NCT00294996_1B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT00294996_1B.rda -------------------------------------------------------------------------------- /data/NCT00337103_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT00337103_2A.rda -------------------------------------------------------------------------------- /data/NCT00337103_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT00337103_2B.rda -------------------------------------------------------------------------------- /data/NCT00596830_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT00596830_2A.rda -------------------------------------------------------------------------------- /data/NCT00596830_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT00596830_2B.rda -------------------------------------------------------------------------------- /data/NCT00614393(a)_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT00614393(a)_3A.rda -------------------------------------------------------------------------------- /data/NCT00614393(a)_3B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT00614393(a)_3B.rda -------------------------------------------------------------------------------- /data/NCT00614393(b)_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT00614393(b)_3A.rda -------------------------------------------------------------------------------- /data/NCT00614393(b)_3B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT00614393(b)_3B.rda -------------------------------------------------------------------------------- /data/NCT00673049_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT00673049_2A.rda -------------------------------------------------------------------------------- /data/NCT00673049_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT00673049_2B.rda -------------------------------------------------------------------------------- /data/NCT00938652_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT00938652_2A.rda -------------------------------------------------------------------------------- /data/NCT00938652_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT00938652_2C.rda -------------------------------------------------------------------------------- /data/NCT01234311_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT01234311_2A.rda -------------------------------------------------------------------------------- /data/NCT01234311_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NCT01234311_2B.rda -------------------------------------------------------------------------------- /data/NITRO_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NITRO_2A.rda -------------------------------------------------------------------------------- /data/NITRO_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NITRO_2B.rda -------------------------------------------------------------------------------- /data/NO16968_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NO16968_2A.rda -------------------------------------------------------------------------------- /data/NO16968_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NO16968_2C.rda -------------------------------------------------------------------------------- /data/NOAH_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NOAH_2A.rda -------------------------------------------------------------------------------- /data/NOAH_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NOAH_2B.rda -------------------------------------------------------------------------------- /data/NSABPB35_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NSABPB35_2.rda -------------------------------------------------------------------------------- /data/NSABPB35_3.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NSABPB35_3.rda -------------------------------------------------------------------------------- /data/NSABPB40_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NSABPB40_3A.rda -------------------------------------------------------------------------------- /data/NSABPB40_3B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NSABPB40_3B.rda -------------------------------------------------------------------------------- /data/NSABPR04_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NSABPR04_3A.rda -------------------------------------------------------------------------------- /data/NSABPR04_3B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NSABPR04_3B.rda -------------------------------------------------------------------------------- /data/NSABPR04_5A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NSABPR04_5A.rda -------------------------------------------------------------------------------- /data/NSABPR04_5B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NSABPR04_5B.rda -------------------------------------------------------------------------------- /data/NTR1527_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NTR1527_2.rda -------------------------------------------------------------------------------- /data/NTR1527_4.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NTR1527_4.rda -------------------------------------------------------------------------------- /data/NeoALTTO(a)_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NeoALTTO(a)_2A.rda -------------------------------------------------------------------------------- /data/NeoALTTO(a)_2D.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NeoALTTO(a)_2D.rda -------------------------------------------------------------------------------- /data/NeoALTTO(b)_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NeoALTTO(b)_2A.rda -------------------------------------------------------------------------------- /data/NeoALTTO(b)_2D.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/NeoALTTO(b)_2D.rda -------------------------------------------------------------------------------- /data/OMEGA_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/OMEGA_3A.rda -------------------------------------------------------------------------------- /data/OMEGA_3B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/OMEGA_3B.rda -------------------------------------------------------------------------------- /data/OPTIMAL_1.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/OPTIMAL_1.rda -------------------------------------------------------------------------------- /data/OPTIMOX3_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/OPTIMOX3_3A.rda -------------------------------------------------------------------------------- /data/OPTIMOX3_3B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/OPTIMOX3_3B.rda -------------------------------------------------------------------------------- /data/PALOMA2_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PALOMA2_1A.rda -------------------------------------------------------------------------------- /data/PALOMA3_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PALOMA3_1A.rda -------------------------------------------------------------------------------- /data/PALOMA3_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PALOMA3_2A.rda -------------------------------------------------------------------------------- /data/PEGASE07_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PEGASE07_2A.rda -------------------------------------------------------------------------------- /data/PEGASE07_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PEGASE07_2B.rda -------------------------------------------------------------------------------- /data/PETACC8_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PETACC8_2A.rda -------------------------------------------------------------------------------- /data/PETACC8_3A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PETACC8_3A.rda -------------------------------------------------------------------------------- /data/PREVAIL_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PREVAIL_1A.rda -------------------------------------------------------------------------------- /data/PREVAIL_1B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PREVAIL_1B.rda -------------------------------------------------------------------------------- /data/PROCLAIM_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PROCLAIM_2A.rda -------------------------------------------------------------------------------- /data/PROCLAIM_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PROCLAIM_2B.rda -------------------------------------------------------------------------------- /data/PROCTOR-SCRIPT_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PROCTOR-SCRIPT_1A.rda -------------------------------------------------------------------------------- /data/PROCTOR-SCRIPT_1B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PROCTOR-SCRIPT_1B.rda -------------------------------------------------------------------------------- /data/PROFILE1014_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PROFILE1014_1A.rda -------------------------------------------------------------------------------- /data/PROFILE1014_1B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PROFILE1014_1B.rda -------------------------------------------------------------------------------- /data/PROFILE1014_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PROFILE1014_2A.rda -------------------------------------------------------------------------------- /data/PROSE_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PROSE_2A.rda -------------------------------------------------------------------------------- /data/PROSE_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/PROSE_2B.rda -------------------------------------------------------------------------------- /data/QUARTZ_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/QUARTZ_2A.rda -------------------------------------------------------------------------------- /data/QUASAR2_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/QUASAR2_2A.rda -------------------------------------------------------------------------------- /data/QUASAR2_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/QUASAR2_2B.rda -------------------------------------------------------------------------------- /data/R98_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/R98_2.rda -------------------------------------------------------------------------------- /data/R98_4.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/R98_4.rda -------------------------------------------------------------------------------- /data/RADIANT4_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/RADIANT4_2A.rda -------------------------------------------------------------------------------- /data/RADIANT4_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/RADIANT4_2C.rda -------------------------------------------------------------------------------- /data/RADIANT_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/RADIANT_2A.rda -------------------------------------------------------------------------------- /data/RAISE_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/RAISE_2A.rda -------------------------------------------------------------------------------- /data/RAISE_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/RAISE_2B.rda -------------------------------------------------------------------------------- /data/RECOURSE_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/RECOURSE_1A.rda -------------------------------------------------------------------------------- /data/RECOURSE_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/RECOURSE_2A.rda -------------------------------------------------------------------------------- /data/REVEL_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/REVEL_2.rda -------------------------------------------------------------------------------- /data/REVEL_3.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/REVEL_3.rda -------------------------------------------------------------------------------- /data/ROSE_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ROSE_2A.rda -------------------------------------------------------------------------------- /data/ROSE_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/ROSE_2C.rda -------------------------------------------------------------------------------- /data/RTOG0415_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/RTOG0415_2.rda -------------------------------------------------------------------------------- /data/RTOG0617_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/RTOG0617_2A.rda -------------------------------------------------------------------------------- /data/RTOG0617_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/RTOG0617_2B.rda -------------------------------------------------------------------------------- /data/RTOG9804_2C.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/RTOG9804_2C.rda -------------------------------------------------------------------------------- /data/RTOG9804_2D.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/RTOG9804_2D.rda -------------------------------------------------------------------------------- /data/SAKK4106_1.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/SAKK4106_1.rda -------------------------------------------------------------------------------- /data/SAKK4106_3.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/SAKK4106_3.rda -------------------------------------------------------------------------------- /data/SAKK_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/SAKK_2A.rda -------------------------------------------------------------------------------- /data/SAKK_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/SAKK_2B.rda -------------------------------------------------------------------------------- /data/SELECTBC_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/SELECTBC_2A.rda -------------------------------------------------------------------------------- /data/SELECTBC_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/SELECTBC_2B.rda -------------------------------------------------------------------------------- /data/SIRFLOX_3.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/SIRFLOX_3.rda -------------------------------------------------------------------------------- /data/SMART_3.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/SMART_3.rda -------------------------------------------------------------------------------- /data/SMX1132531_1.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/SMX1132531_1.rda -------------------------------------------------------------------------------- /data/SOFT_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/SOFT_2A.rda -------------------------------------------------------------------------------- /data/SQUIRE_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/SQUIRE_2A.rda -------------------------------------------------------------------------------- /data/SQUIRE_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/SQUIRE_2B.rda -------------------------------------------------------------------------------- /data/TANIA_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/TANIA_2.rda -------------------------------------------------------------------------------- /data/TCOG0701_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/TCOG0701_1A.rda -------------------------------------------------------------------------------- /data/TCOG0701_1B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/TCOG0701_1B.rda -------------------------------------------------------------------------------- /data/TEXT-SOFT(2)_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/TEXT-SOFT(2)_2A.rda -------------------------------------------------------------------------------- /data/TEXT-SOFT(2)_2D.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/TEXT-SOFT(2)_2D.rda -------------------------------------------------------------------------------- /data/TH3RESA_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/TH3RESA_2A.rda -------------------------------------------------------------------------------- /data/TH3RESA_4.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/TH3RESA_4.rda -------------------------------------------------------------------------------- /data/TRAPEZE_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/TRAPEZE_1A.rda -------------------------------------------------------------------------------- /data/TRAPEZE_1B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/TRAPEZE_1B.rda -------------------------------------------------------------------------------- /data/TRIBE(2)_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/TRIBE(2)_2A.rda -------------------------------------------------------------------------------- /data/TRIBE(2)_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/TRIBE(2)_2B.rda -------------------------------------------------------------------------------- /data/TRIBE_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/TRIBE_2.rda -------------------------------------------------------------------------------- /data/TROG0306_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/TROG0306_2.rda -------------------------------------------------------------------------------- /data/TURANDOT_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/TURANDOT_2B.rda -------------------------------------------------------------------------------- /data/TURANDOT_3.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/TURANDOT_3.rda -------------------------------------------------------------------------------- /data/VANTAGE014_2.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/VANTAGE014_2.rda -------------------------------------------------------------------------------- /data/VANTAGE014_4.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/VANTAGE014_4.rda -------------------------------------------------------------------------------- /data/WJOG5108L_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/WJOG5108L_2A.rda -------------------------------------------------------------------------------- /data/WJOG5108L_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/WJOG5108L_2B.rda -------------------------------------------------------------------------------- /data/WJOG5208L_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/WJOG5208L_2A.rda -------------------------------------------------------------------------------- /data/WJOG5208L_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/WJOG5208L_2B.rda -------------------------------------------------------------------------------- /data/WSG-ARA_3.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/WSG-ARA_3.rda -------------------------------------------------------------------------------- /data/WSGAGO_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/WSGAGO_2A.rda -------------------------------------------------------------------------------- /data/X20050181_1A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/X20050181_1A.rda -------------------------------------------------------------------------------- /data/X20050181_1B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/X20050181_1B.rda -------------------------------------------------------------------------------- /data/X20050181_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/X20050181_2A.rda -------------------------------------------------------------------------------- /data/X20050181_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/X20050181_2B.rda -------------------------------------------------------------------------------- /data/X2005B3030_2A.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/X2005B3030_2A.rda -------------------------------------------------------------------------------- /data/X2005B3030_2B.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/X2005B3030_2B.rda -------------------------------------------------------------------------------- /data/kmdata_demo.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/kmdata_demo.rda -------------------------------------------------------------------------------- /data/kmdata_key.rda: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/data/kmdata_key.rda -------------------------------------------------------------------------------- /inst/docs/Citations_final.xlsx: -------------------------------------------------------------------------------- https://raw.githubusercontent.com/raredd/kmdata/7de3714211c26c0beb18e732dd78440d4a0e9a01/inst/docs/Citations_final.xlsx -------------------------------------------------------------------------------- /inst/etc/init/Checkmate_067_At_Risk.csv: -------------------------------------------------------------------------------- 1 | interval,trisk,lower,upper,nrisk,TE,StudyID,Figure#,Arm 2 | 1,0,,,80,,Checkmate 067,S3A,Nivolumab 3 | 2,3,,,79,,Checkmate 067,S3A,Nivolumab 4 | 3,6,,,75,,Checkmate 067,S3A,Nivolumab 5 | 4,9,,,73,,Checkmate 067,S3A,Nivolumab 6 | 5,12,,,68,,Checkmate 067,S3A,Nivolumab 7 | 6,15,,,63,,Checkmate 067,S3A,Nivolumab 8 | 7,18,,,61,,Checkmate 067,S3A,Nivolumab 9 | 8,21,,,58,,Checkmate 067,S3A,Nivolumab 10 | 9,24,,,57,,Checkmate 067,S3A,Nivolumab 11 | 10,27,,,54,,Checkmate 067,S3A,Nivolumab 12 | 11,30,,,53,,Checkmate 067,S3A,Nivolumab 13 | 12,33,,,49,,Checkmate 067,S3A,Nivolumab 14 | 13,36,,,47,,Checkmate 067,S3A,Nivolumab 15 | 14,39,,,38,,Checkmate 067,S3A,Nivolumab 16 | 15,42,,,10,,Checkmate 067,S3A,Nivolumab 17 | 16,45,,,0,,Checkmate 067,S3A,Nivolumab -------------------------------------------------------------------------------- /man/ACT1_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ACT1_2A} 5 | \alias{ACT1_2A} 6 | \title{ACT1, figure 2A} 7 | \format{ 8 | A data frame of 637 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (amrubicin, topotecan) \cr 13 | } 14 | } 15 | \source{ 16 | von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of 17 | amrubicin versus topotecan as second-line treatment for patients with 18 | small-cell lung cancer. J Clin Oncol 2014; 32: 4012–9. 19 | } 20 | \usage{ 21 | ACT1_2A 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from ACT1, figure 2A (PMID 25385727). A reported sample size of 637 for a primary endpoint of OS in lung cancer. 25 | } 26 | \examples{ 27 | summary(ACT1_2A) 28 | 29 | kmplot(ACT1_2A) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/ACT1_3A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ACT1_3A} 5 | \alias{ACT1_3A} 6 | \title{ACT1, figure 3A} 7 | \format{ 8 | A data frame of 637 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (amrubicin, topotecan) \cr 13 | } 14 | } 15 | \source{ 16 | von Pawel J, Jotte R, Spigel DR, et al. Randomized phase III trial of 17 | amrubicin versus topotecan as second-line treatment for patients with 18 | small-cell lung cancer. J Clin Oncol 2014; 32: 4012–9. 19 | } 20 | \usage{ 21 | ACT1_3A 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from ACT1, figure 3A (PMID 25385727). A reported sample size of 637 for a primary endpoint of OS in lung cancer. 25 | } 26 | \examples{ 27 | summary(ACT1_3A) 28 | 29 | kmplot(ACT1_3A) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/ACT2_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ACT2_2A} 5 | \alias{ACT2_2A} 6 | \title{ACT2, figure 2A} 7 | \format{ 8 | A data frame of 71 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (wt_b, wt_be) \cr 13 | } 14 | } 15 | \source{ 16 | Hagman H, Frödin J-E, Berglund Å, et al. A randomized study of 17 | KRAS-guided maintenance therapy with bevacizumab, erlotinib or 18 | metronomic capecitabine after first-line induction treatment of 19 | metastatic colorectal cancer: the Nordic ACT2 trial. Ann Oncol 2016; 20 | 27: 140–7. 21 | } 22 | \usage{ 23 | ACT2_2A 24 | } 25 | \description{ 26 | Kaplan-Meier digitized data from ACT2, figure 2A (PMID 26483047). A reported sample size of 233 for a primary endpoint of PFS-3mo in colorectal cancer. 27 | } 28 | \examples{ 29 | summary(ACT2_2A) 30 | 31 | kmplot(ACT2_2A) 32 | } 33 | \keyword{datasets} 34 | -------------------------------------------------------------------------------- /man/ACTSCC_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ACTSCC_2A} 5 | \alias{ACTSCC_2A} 6 | \title{ACTSCC, figure 2A} 7 | \format{ 8 | A data frame of 1,518 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (s_1, uft_lv) \cr 13 | } 14 | } 15 | \source{ 16 | Yoshida M, Ishiguro M, Ikejiri K, et al. S-1 as adjuvant chemotherapy 17 | for stage III colon cancer: a randomized phase III study (ACTS-CC 18 | trial). Ann Oncol 2014; 25: 1743–9. 19 | } 20 | \usage{ 21 | ACTSCC_2A 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from ACTSCC, figure 2A (PMID 24942277). A reported sample size of 1,518 for a primary endpoint of DFS_3yr in colorectal cancer. 25 | } 26 | \examples{ 27 | summary(ACTSCC_2A) 28 | 29 | kmplot(ACTSCC_2A) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/AURA3_1A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{AURA3_1A} 5 | \alias{AURA3_1A} 6 | \title{AURA3, figure 1A} 7 | \format{ 8 | A data frame of 419 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (osimertinib, platinum-pemetrexed) \cr 13 | } 14 | } 15 | \source{ 16 | Mok TS, Wu Y-L, Ahn M-J, et al. Osimertinib or Platinum-Pemetrexed in 17 | EGFR T790M-Positive Lung Cancer. N Engl J Med 2017; 376: 629–40. 18 | } 19 | \usage{ 20 | AURA3_1A 21 | } 22 | \description{ 23 | Kaplan-Meier digitized data from AURA3, figure 1A (PMID 27959700). A reported sample size of 419 for a primary endpoint of PFS in lung cancer. 24 | } 25 | \examples{ 26 | summary(AURA3_1A) 27 | 28 | kmplot(AURA3_1A) 29 | } 30 | \keyword{datasets} 31 | -------------------------------------------------------------------------------- /man/AZURE_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{AZURE_2A} 5 | \alias{AZURE_2A} 6 | \title{AZURE, figure 2A} 7 | \format{ 8 | A data frame of 3,359 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (control, zoledronic_acid) \cr 13 | } 14 | } 15 | \source{ 16 | Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in 17 | patients with early breast cancer: final efficacy analysis of the 18 | AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 19 | 2014; 15: 997–1006. 20 | } 21 | \usage{ 22 | AZURE_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from AZURE, figure 2A (PMID 25035292). A reported sample size of 3,360 for a primary endpoint of DFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(AZURE_2A) 29 | 30 | kmplot(AZURE_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/AZURE_4.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{AZURE_4} 5 | \alias{AZURE_4} 6 | \title{AZURE, figure 4} 7 | \format{ 8 | A data frame of 3,359 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (control, zoledronic_acid) \cr 13 | } 14 | } 15 | \source{ 16 | Coleman R, Cameron D, Dodwell D, et al. Adjuvant zoledronic acid in 17 | patients with early breast cancer: final efficacy analysis of the 18 | AZURE (BIG 01/04) randomised open-label phase 3 trial. Lancet Oncol 19 | 2014; 15: 997–1006. 20 | } 21 | \usage{ 22 | AZURE_4 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from AZURE, figure 4 (PMID 25035292). A reported sample size of 3,360 for a primary endpoint of DFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(AZURE_4) 29 | 30 | kmplot(AZURE_4) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/BEBYP_1.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{BEBYP_1} 5 | \alias{BEBYP_1} 6 | \title{BEBYP, figure 1} 7 | \format{ 8 | A data frame of 184 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (bev_ct, ct) \cr 13 | } 14 | } 15 | \source{ 16 | Masi G, Salvatore L, Boni L, et al. Continuation or reintroduction of 17 | bevacizumab beyond progression to first-line therapy in metastatic 18 | colorectal cancer: final results of the randomized BEBYP trial. Ann 19 | Oncol 2015; 26: 724–30. 20 | } 21 | \usage{ 22 | BEBYP_1 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from BEBYP, figure 1 (PMID 25600568). A reported sample size of 185 for a primary endpoint of PFS in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(BEBYP_1) 29 | 30 | kmplot(BEBYP_1) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/BEBYP_3.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{BEBYP_3} 5 | \alias{BEBYP_3} 6 | \title{BEBYP, figure 3} 7 | \format{ 8 | A data frame of 184 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (bev_ct, ct) \cr 13 | } 14 | } 15 | \source{ 16 | Masi G, Salvatore L, Boni L, et al. Continuation or reintroduction of 17 | bevacizumab beyond progression to first-line therapy in metastatic 18 | colorectal cancer: final results of the randomized BEBYP trial. Ann 19 | Oncol 2015; 26: 724–30. 20 | } 21 | \usage{ 22 | BEBYP_3 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from BEBYP, figure 3 (PMID 25600568). A reported sample size of 185 for a primary endpoint of PFS in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(BEBYP_3) 29 | 30 | kmplot(BEBYP_3) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/BOLERO2_1.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{BOLERO2_1} 5 | \alias{BOLERO2_1} 6 | \title{BOLERO2, figure 1} 7 | \format{ 8 | A data frame of 724 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (eve_exe, pbo_exe) \cr 13 | } 14 | } 15 | \source{ 16 | Piccart M, Hortobagyi GN, Campone M, et al. Everolimus plus 17 | exemestane for hormone-receptor-positive, human epidermal growth 18 | factor receptor-2-negative advanced breast cancer: overall survival 19 | results from BOLERO-2†. Ann Oncol 2014; 25: 2357–62. 20 | } 21 | \usage{ 22 | BOLERO2_1 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from BOLERO2, figure 1 (PMID 25231953). A reported sample size of 720 for a primary endpoint of PFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(BOLERO2_1) 29 | 30 | kmplot(BOLERO2_1) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/BOLERO3_2.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{BOLERO3_2} 5 | \alias{BOLERO3_2} 6 | \title{BOLERO3, figure 2} 7 | \format{ 8 | A data frame of 569 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in weeks) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (eve_exe, placebo) \cr 13 | } 14 | } 15 | \source{ 16 | André F, O’Regan R, Ozguroglu M, et al. Everolimus for women with 17 | trastuzumab-resistant, HER2-positive, advanced breast cancer 18 | (BOLERO-3): a randomised, double-blind, placebo-controlled phase 3 19 | trial. Lancet Oncol 2014; 15: 580–91. 20 | } 21 | \usage{ 22 | BOLERO3_2 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from BOLERO3, figure 2 (PMID 24742739). A reported sample size of 569 for a primary endpoint of PFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(BOLERO3_2) 29 | 30 | kmplot(BOLERO3_2) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/BREC_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{BREC_2A} 5 | \alias{BREC_2A} 6 | \title{BREC, figure 2A} 7 | \format{ 8 | A data frame of 277 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (control, experimental) \cr 13 | } 14 | } 15 | \source{ 16 | Moran T, Wei J, Cobo M, et al. Two biomarker-directed randomized 17 | trials in European and Chinese patients with nonsmall-cell lung 18 | cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Ann 19 | Oncol 2014; 25: 2147–55. 20 | } 21 | \usage{ 22 | BREC_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from BREC, figure 2A (PMID 25164908). A reported sample size of 279 for a primary endpoint of PFS in lung cancer. 26 | } 27 | \examples{ 28 | summary(BREC_2A) 29 | 30 | kmplot(BREC_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/BREC_2C.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{BREC_2C} 5 | \alias{BREC_2C} 6 | \title{BREC, figure 2C} 7 | \format{ 8 | A data frame of 124 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (control, experimental) \cr 13 | } 14 | } 15 | \source{ 16 | Moran T, Wei J, Cobo M, et al. Two biomarker-directed randomized 17 | trials in European and Chinese patients with nonsmall-cell lung 18 | cancer: the BRCA1-RAP80 Expression Customization (BREC) studies. Ann 19 | Oncol 2014; 25: 2147–55. 20 | } 21 | \usage{ 22 | BREC_2C 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from BREC, figure 2C (PMID 25164908). A reported sample size of 279 for a primary endpoint of PFS in lung cancer. 26 | } 27 | \examples{ 28 | summary(BREC_2C) 29 | 30 | kmplot(BREC_2C) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/CA097375_2.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{CA097375_2} 5 | \alias{CA097375_2} 6 | \title{CA097375, figure 2} 7 | \format{ 8 | A data frame of 499 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (a, b) \cr 13 | } 14 | } 15 | \source{ 16 | Love RR, Laudico AV, Van Dinh N, et al. Timing of adjuvant surgical 17 | oophorectomy in the menstrual cycle and disease-free and overall 18 | survival in premenopausal women with operable breast cancer. J Natl 19 | Cancer Inst 2015; 107: djv064. 20 | } 21 | \usage{ 22 | CA097375_2 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from CA097375, figure 2 (PMID 25794890). A reported sample size of 740 for a primary endpoint of DFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(CA097375_2) 29 | 30 | kmplot(CA097375_2) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/CA097375_3.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{CA097375_3} 5 | \alias{CA097375_3} 6 | \title{CA097375, figure 3} 7 | \format{ 8 | A data frame of 499 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (a, b) \cr 13 | } 14 | } 15 | \source{ 16 | Love RR, Laudico AV, Van Dinh N, et al. Timing of adjuvant surgical 17 | oophorectomy in the menstrual cycle and disease-free and overall 18 | survival in premenopausal women with operable breast cancer. J Natl 19 | Cancer Inst 2015; 107: djv064. 20 | } 21 | \usage{ 22 | CA097375_3 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from CA097375, figure 3 (PMID 25794890). A reported sample size of 740 for a primary endpoint of DFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(CA097375_3) 29 | 30 | kmplot(CA097375_3) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/CAIRO3_2D.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{CAIRO3_2D} 5 | \alias{CAIRO3_2D} 6 | \title{CAIRO3, figure 2D} 7 | \format{ 8 | A data frame of 557 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (maintenance, observation) \cr 13 | } 14 | } 15 | \source{ 16 | Simkens LHJ, van Tinteren H, May A, et al. Maintenance treatment with 17 | capecitabine and bevacizumab in metastatic colorectal cancer 18 | (CAIRO3): a phase 3 randomised controlled trial of the Dutch 19 | Colorectal Cancer Group. Lancet 2015; 385: 1843–52. 20 | } 21 | \usage{ 22 | CAIRO3_2D 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from CAIRO3, figure 2D (PMID 25862517). A reported sample size of 558 for a primary endpoint of PFS2 in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(CAIRO3_2D) 29 | 30 | kmplot(CAIRO3_2D) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/CLEOPATRA_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{CLEOPATRA_2A} 5 | \alias{CLEOPATRA_2A} 6 | \title{CLEOPATRA, figure 2A} 7 | \format{ 8 | A data frame of 808 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (control, pertuzumab) \cr 13 | } 14 | } 15 | \source{ 16 | Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and 17 | docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 18 | 2015; 372: 724–34. 19 | } 20 | \usage{ 21 | CLEOPATRA_2A 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from CLEOPATRA, figure 2A (PMID 25693012). A reported sample size of 808 for a primary endpoint of PFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(CLEOPATRA_2A) 28 | 29 | kmplot(CLEOPATRA_2A) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/CLEOPATRA_3A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{CLEOPATRA_3A} 5 | \alias{CLEOPATRA_3A} 6 | \title{CLEOPATRA, figure 3A} 7 | \format{ 8 | A data frame of 808 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (control, pertuzumab) \cr 13 | } 14 | } 15 | \source{ 16 | Swain SM, Baselga J, Kim S-B, et al. Pertuzumab, trastuzumab, and 17 | docetaxel in HER2-positive metastatic breast cancer. N Engl J Med 18 | 2015; 372: 724–34. 19 | } 20 | \usage{ 21 | CLEOPATRA_3A 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from CLEOPATRA, figure 3A (PMID 25693012). A reported sample size of 808 for a primary endpoint of PFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(CLEOPATRA_3A) 28 | 29 | kmplot(CLEOPATRA_3A) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/COMET1_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{COMET1_2A} 5 | \alias{COMET1_2A} 6 | \title{COMET1, figure 2A} 7 | \format{ 8 | A data frame of 1,028 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (cabozantinib, prednisone) \cr 13 | } 14 | } 15 | \source{ 16 | Smith M, De Bono J, Sternberg C, et al. Phase III Study of 17 | Cabozantinib in Previously Treated Metastatic Castration-Resistant 18 | Prostate Cancer: COMET-1. J Clin Oncol 2016; 34: 3005–13. 19 | } 20 | \usage{ 21 | COMET1_2A 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from COMET1, figure 2A (PMID 27400947). A reported sample size of 1,028 for a primary endpoint of OS in prostate cancer. 25 | } 26 | \examples{ 27 | summary(COMET1_2A) 28 | 29 | kmplot(COMET1_2A) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/COMET1_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{COMET1_2B} 5 | \alias{COMET1_2B} 6 | \title{COMET1, figure 2B} 7 | \format{ 8 | A data frame of 1,028 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (cabozantinib, prednisone) \cr 13 | } 14 | } 15 | \source{ 16 | Smith M, De Bono J, Sternberg C, et al. Phase III Study of 17 | Cabozantinib in Previously Treated Metastatic Castration-Resistant 18 | Prostate Cancer: COMET-1. J Clin Oncol 2016; 34: 3005–13. 19 | } 20 | \usage{ 21 | COMET1_2B 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from COMET1, figure 2B (PMID 27400947). A reported sample size of 1,028 for a primary endpoint of OS in prostate cancer. 25 | } 26 | \examples{ 27 | summary(COMET1_2B) 28 | 29 | kmplot(COMET1_2B) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/CONCEPT_1A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{CONCEPT_1A} 5 | \alias{CONCEPT_1A} 6 | \title{CONCEPT, figure 1A} 7 | \format{ 8 | A data frame of 139 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab TTF event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (co, io) \cr 13 | } 14 | } 15 | \source{ 16 | Hochster HS, Grothey A, Hart L, et al. Improved time to treatment 17 | failure with an intermittent oxaliplatin strategy: results of 18 | CONcePT. Ann Oncol 2014; 25: 1172–8. 19 | } 20 | \usage{ 21 | CONCEPT_1A 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from CONCEPT, figure 1A (PMID 24608198). A reported sample size of 140 for a primary endpoint of TTF in colorectal cancer. 25 | } 26 | \examples{ 27 | summary(CONCEPT_1A) 28 | 29 | kmplot(CONCEPT_1A) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/Checkmate017_1.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{Checkmate017_1} 5 | \alias{Checkmate017_1} 6 | \title{Checkmate017, figure 1} 7 | \format{ 8 | A data frame of 272 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (d1, nivolumab) \cr 13 | } 14 | } 15 | \source{ 16 | Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in 17 | Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 18 | 373: 123–35. 19 | } 20 | \usage{ 21 | Checkmate017_1 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from Checkmate017, figure 1 (PMID 26028407). A reported sample size of 272 for a primary endpoint of OS in lung cancer. 25 | } 26 | \examples{ 27 | summary(Checkmate017_1) 28 | 29 | kmplot(Checkmate017_1) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/Checkmate017_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{Checkmate017_2B} 5 | \alias{Checkmate017_2B} 6 | \title{Checkmate017, figure 2B} 7 | \format{ 8 | A data frame of 272 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (d1, nivolumab) \cr 13 | } 14 | } 15 | \source{ 16 | Brahmer J, Reckamp KL, Baas P, et al. Nivolumab versus Docetaxel in 17 | Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med 2015; 18 | 373: 123–35. 19 | } 20 | \usage{ 21 | Checkmate017_2B 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from Checkmate017, figure 2B (PMID 26028407). A reported sample size of 272 for a primary endpoint of OS in lung cancer. 25 | } 26 | \examples{ 27 | summary(Checkmate017_2B) 28 | 29 | kmplot(Checkmate017_2B) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/Checkmate057_1A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{Checkmate057_1A} 5 | \alias{Checkmate057_1A} 6 | \title{Checkmate057, figure 1A} 7 | \format{ 8 | A data frame of 582 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (d1, nivolumab) \cr 13 | } 14 | } 15 | \source{ 16 | Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in 17 | Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015; 18 | 373: 1627–39. 19 | } 20 | \usage{ 21 | Checkmate057_1A 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from Checkmate057, figure 1A (PMID 26412456). A reported sample size of 582 for a primary endpoint of OS in lung cancer. 25 | } 26 | \examples{ 27 | summary(Checkmate057_1A) 28 | 29 | kmplot(Checkmate057_1A) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/Checkmate057_1C.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{Checkmate057_1C} 5 | \alias{Checkmate057_1C} 6 | \title{Checkmate057, figure 1C} 7 | \format{ 8 | A data frame of 582 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (d1, nivolumab) \cr 13 | } 14 | } 15 | \source{ 16 | Borghaei H, Paz-Ares L, Horn L, et al. Nivolumab versus Docetaxel in 17 | Advanced Nonsquamous Non-Small-Cell Lung Cancer. N Engl J Med 2015; 18 | 373: 1627–39. 19 | } 20 | \usage{ 21 | Checkmate057_1C 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from Checkmate057, figure 1C (PMID 26412456). A reported sample size of 582 for a primary endpoint of OS in lung cancer. 25 | } 26 | \examples{ 27 | summary(Checkmate057_1C) 28 | 29 | kmplot(Checkmate057_1C) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/DART0105_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{DART0105_2A} 5 | \alias{DART0105_2A} 6 | \title{DART0105, figure 2A} 7 | \format{ 8 | A data frame of 343 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (ltad, stad) \cr 13 | } 14 | } 15 | \source{ 16 | Zapatero A, Guerrero A, Maldonado X, et al. High-dose radiotherapy 17 | with short-term or long-term androgen deprivation in localised 18 | prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 19 | trial. Lancet Oncol 2015; 16: 320–7. 20 | } 21 | \usage{ 22 | DART0105_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from DART0105, figure 2A (PMID 25702876). A reported sample size of 178 for a primary endpoint of bDFS in prostate cancer. 26 | } 27 | \examples{ 28 | summary(DART0105_2A) 29 | 30 | kmplot(DART0105_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/DART0105_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{DART0105_2B} 5 | \alias{DART0105_2B} 6 | \title{DART0105, figure 2B} 7 | \format{ 8 | A data frame of 347 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (ltad, stad) \cr 13 | } 14 | } 15 | \source{ 16 | Zapatero A, Guerrero A, Maldonado X, et al. High-dose radiotherapy 17 | with short-term or long-term androgen deprivation in localised 18 | prostate cancer (DART01/05 GICOR): a randomised, controlled, phase 3 19 | trial. Lancet Oncol 2015; 16: 320–7. 20 | } 21 | \usage{ 22 | DART0105_2B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from DART0105, figure 2B (PMID 25702876). A reported sample size of 178 for a primary endpoint of bDFS in prostate cancer. 26 | } 27 | \examples{ 28 | summary(DART0105_2B) 29 | 30 | kmplot(DART0105_2B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/DELTA_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{DELTA_2A} 5 | \alias{DELTA_2A} 6 | \title{DELTA, figure 2A} 7 | \format{ 8 | A data frame of 301 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (d1, erlotinib) \cr 13 | } 14 | } 15 | \source{ 16 | Kawaguchi T, Ando M, Asami K, et al. Randomized phase III trial of 17 | erlotinib versus docetaxel as second- or third-line therapy in 18 | patients with advanced non-small-cell lung cancer: Docetaxel and 19 | Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2014; 32: 1902–8. 20 | } 21 | \usage{ 22 | DELTA_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from DELTA, figure 2A (PMID 24841974). A reported sample size of 301 for a primary endpoint of PFS in lung cancer. 26 | } 27 | \examples{ 28 | summary(DELTA_2A) 29 | 30 | kmplot(DELTA_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/DELTA_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{DELTA_2B} 5 | \alias{DELTA_2B} 6 | \title{DELTA, figure 2B} 7 | \format{ 8 | A data frame of 301 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (d1, erlotinib) \cr 13 | } 14 | } 15 | \source{ 16 | Kawaguchi T, Ando M, Asami K, et al. Randomized phase III trial of 17 | erlotinib versus docetaxel as second- or third-line therapy in 18 | patients with advanced non-small-cell lung cancer: Docetaxel and 19 | Erlotinib Lung Cancer Trial (DELTA). J Clin Oncol 2014; 32: 1902–8. 20 | } 21 | \usage{ 22 | DELTA_2B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from DELTA, figure 2B (PMID 24841974). A reported sample size of 301 for a primary endpoint of PFS in lung cancer. 26 | } 27 | \examples{ 28 | summary(DELTA_2B) 29 | 30 | kmplot(DELTA_2B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/E1199-open-paren-a-close-paren-_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{E1199(a)_2A} 5 | \alias{E1199(a)_2A} 6 | \title{E1199(a), figure 2A} 7 | \format{ 8 | A data frame of 2,481 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (p1, p3) \cr 13 | } 14 | } 15 | \source{ 16 | Sparano JA, Zhao F, Martino S, et al. Long-Term Follow-Up of the 17 | E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in 18 | Operable Breast Cancer. J Clin Oncol 2015; 33: 2353–60. 19 | } 20 | \usage{ 21 | `E1199(a)_2A` 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from E1199(a), figure 2A (PMID 26077235). A reported sample size of 4,954 for a primary endpoint of DFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(`E1199(a)_2A`) 28 | 29 | kmplot(`E1199(a)_2A`) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/E1199-open-paren-a-close-paren-_2C.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{E1199(a)_2C} 5 | \alias{E1199(a)_2C} 6 | \title{E1199(a), figure 2C} 7 | \format{ 8 | A data frame of 2,481 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (p1, p3) \cr 13 | } 14 | } 15 | \source{ 16 | Sparano JA, Zhao F, Martino S, et al. Long-Term Follow-Up of the 17 | E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in 18 | Operable Breast Cancer. J Clin Oncol 2015; 33: 2353–60. 19 | } 20 | \usage{ 21 | `E1199(a)_2C` 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from E1199(a), figure 2C (PMID 26077235). A reported sample size of 4,954 for a primary endpoint of DFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(`E1199(a)_2C`) 28 | 29 | kmplot(`E1199(a)_2C`) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/E1199-open-paren-b-close-paren-_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{E1199(b)_2A} 5 | \alias{E1199(b)_2A} 6 | \title{E1199(b), figure 2A} 7 | \format{ 8 | A data frame of 2,484 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (d3, p3) \cr 13 | } 14 | } 15 | \source{ 16 | Sparano JA, Zhao F, Martino S, et al. Long-Term Follow-Up of the 17 | E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in 18 | Operable Breast Cancer. J Clin Oncol 2015; 33: 2353–60. 19 | } 20 | \usage{ 21 | `E1199(b)_2A` 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from E1199(b), figure 2A (PMID 26077235). A reported sample size of 4,954 for a primary endpoint of DFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(`E1199(b)_2A`) 28 | 29 | kmplot(`E1199(b)_2A`) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/E1199-open-paren-b-close-paren-_2C.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{E1199(b)_2C} 5 | \alias{E1199(b)_2C} 6 | \title{E1199(b), figure 2C} 7 | \format{ 8 | A data frame of 2,484 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (d3, p3) \cr 13 | } 14 | } 15 | \source{ 16 | Sparano JA, Zhao F, Martino S, et al. Long-Term Follow-Up of the 17 | E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in 18 | Operable Breast Cancer. J Clin Oncol 2015; 33: 2353–60. 19 | } 20 | \usage{ 21 | `E1199(b)_2C` 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from E1199(b), figure 2C (PMID 26077235). A reported sample size of 4,954 for a primary endpoint of DFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(`E1199(b)_2C`) 28 | 29 | kmplot(`E1199(b)_2C`) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/E1199-open-paren-c-close-paren-_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{E1199(c)_2A} 5 | \alias{E1199(c)_2A} 6 | \title{E1199(c), figure 2A} 7 | \format{ 8 | A data frame of 2,483 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (d1, p3) \cr 13 | } 14 | } 15 | \source{ 16 | Sparano JA, Zhao F, Martino S, et al. Long-Term Follow-Up of the 17 | E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in 18 | Operable Breast Cancer. J Clin Oncol 2015; 33: 2353–60. 19 | } 20 | \usage{ 21 | `E1199(c)_2A` 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from E1199(c), figure 2A (PMID 26077235). A reported sample size of 4,954 for a primary endpoint of DFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(`E1199(c)_2A`) 28 | 29 | kmplot(`E1199(c)_2A`) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/E1199-open-paren-c-close-paren-_2C.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{E1199(c)_2C} 5 | \alias{E1199(c)_2C} 6 | \title{E1199(c), figure 2C} 7 | \format{ 8 | A data frame of 2,483 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (d1, p3) \cr 13 | } 14 | } 15 | \source{ 16 | Sparano JA, Zhao F, Martino S, et al. Long-Term Follow-Up of the 17 | E1199 Phase III Trial Evaluating the Role of Taxane and Schedule in 18 | Operable Breast Cancer. J Clin Oncol 2015; 33: 2353–60. 19 | } 20 | \usage{ 21 | `E1199(c)_2C` 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from E1199(c), figure 2C (PMID 26077235). A reported sample size of 4,954 for a primary endpoint of DFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(`E1199(c)_2C`) 28 | 29 | kmplot(`E1199(c)_2C`) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/EAGLE_1.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{EAGLE_1} 5 | \alias{EAGLE_1} 6 | \title{EAGLE, figure 1} 7 | \format{ 8 | A data frame of 368 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (bev10, bev5) \cr 13 | } 14 | } 15 | \source{ 16 | Iwamoto S, Takahashi T, Tamagawa H, et al. FOLFIRI plus bevacizumab 17 | as second-line therapy in patients with metastatic colorectal cancer 18 | after first-line bevacizumab plus oxaliplatin-based therapy: the 19 | randomized phase III EAGLE study. Ann Oncol 2015; 26: 1427–33. 20 | } 21 | \usage{ 22 | EAGLE_1 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from EAGLE, figure 1 (PMID 25908603). A reported sample size of 369 for a primary endpoint of PFS in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(EAGLE_1) 29 | 30 | kmplot(EAGLE_1) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/ELDA_1A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ELDA_1A} 5 | \alias{ELDA_1A} 6 | \title{ELDA, figure 1A} 7 | \format{ 8 | A data frame of 299 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (cmf, wdocetaxel) \cr 13 | } 14 | } 15 | \source{ 16 | Perrone F, Nuzzo F, Di Rella F, et al. Weekly docetaxel versus CMF as 17 | adjuvant chemotherapy for older women with early breast cancer: final 18 | results of the randomized phase III ELDA trial. Ann Oncol 2015; 26: 19 | 675–82. 20 | } 21 | \usage{ 22 | ELDA_1A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from ELDA, figure 1A (PMID 25488686). A reported sample size of 302 for a primary endpoint of DFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(ELDA_1A) 29 | 30 | kmplot(ELDA_1A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/ELDA_1B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ELDA_1B} 5 | \alias{ELDA_1B} 6 | \title{ELDA, figure 1B} 7 | \format{ 8 | A data frame of 299 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (cmf, wdocetaxel) \cr 13 | } 14 | } 15 | \source{ 16 | Perrone F, Nuzzo F, Di Rella F, et al. Weekly docetaxel versus CMF as 17 | adjuvant chemotherapy for older women with early breast cancer: final 18 | results of the randomized phase III ELDA trial. Ann Oncol 2015; 26: 19 | 675–82. 20 | } 21 | \usage{ 22 | ELDA_1B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from ELDA, figure 1B (PMID 25488686). A reported sample size of 302 for a primary endpoint of DFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(ELDA_1B) 29 | 30 | kmplot(ELDA_1B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/ENESTg1_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ENESTg1_2A} 5 | \alias{ENESTg1_2A} 6 | \title{ENESTg1, figure 2A} 7 | \format{ 8 | A data frame of 644 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (imatinib, nilotinib) \cr 13 | } 14 | } 15 | \source{ 16 | Blay J-Y, Shen L, Kang Y-K, et al. Nilotinib versus imatinib as 17 | first-line therapy for patients with unresectable or metastatic 18 | gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 19 | trial. Lancet Oncol 2015; 16: 550–60. 20 | } 21 | \usage{ 22 | ENESTg1_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from ENESTg1, figure 2A (PMID 25882987). A reported sample size of 647 for a primary endpoint of PFS in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(ENESTg1_2A) 29 | 30 | kmplot(ENESTg1_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/ENESTg1_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ENESTg1_2B} 5 | \alias{ENESTg1_2B} 6 | \title{ENESTg1, figure 2B} 7 | \format{ 8 | A data frame of 644 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (imatinib, nilotinib) \cr 13 | } 14 | } 15 | \source{ 16 | Blay J-Y, Shen L, Kang Y-K, et al. Nilotinib versus imatinib as 17 | first-line therapy for patients with unresectable or metastatic 18 | gastrointestinal stromal tumours (ENESTg1): a randomised phase 3 19 | trial. Lancet Oncol 2015; 16: 550–60. 20 | } 21 | \usage{ 22 | ENESTg1_2B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from ENESTg1, figure 2B (PMID 25882987). A reported sample size of 647 for a primary endpoint of PFS in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(ENESTg1_2B) 29 | 30 | kmplot(ENESTg1_2B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/ENSURE_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ENSURE_2A} 5 | \alias{ENSURE_2A} 6 | \title{ENSURE, figure 2A} 7 | \format{ 8 | A data frame of 217 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (erlotinib, gp) \cr 13 | } 14 | } 15 | \source{ 16 | Wu Y-L, Zhou C, Liam C-K, et al. First-line erlotinib versus 17 | gemcitabine/cisplatin in patients with advanced EGFR 18 | mutation-positive non-small-cell lung cancer: analyses from the phase 19 | III, randomized, open-label, ENSURE study. Ann Oncol 2015; 26: 20 | 1883–9. 21 | } 22 | \usage{ 23 | ENSURE_2A 24 | } 25 | \description{ 26 | Kaplan-Meier digitized data from ENSURE, figure 2A (PMID 26105600). A reported sample size of 217 for a primary endpoint of PFS in lung cancer. 27 | } 28 | \examples{ 29 | summary(ENSURE_2A) 30 | 31 | kmplot(ENSURE_2A) 32 | } 33 | \keyword{datasets} 34 | -------------------------------------------------------------------------------- /man/ENSURE_3A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ENSURE_3A} 5 | \alias{ENSURE_3A} 6 | \title{ENSURE, figure 3A} 7 | \format{ 8 | A data frame of 217 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (erlotinib, gp) \cr 13 | } 14 | } 15 | \source{ 16 | Wu Y-L, Zhou C, Liam C-K, et al. First-line erlotinib versus 17 | gemcitabine/cisplatin in patients with advanced EGFR 18 | mutation-positive non-small-cell lung cancer: analyses from the phase 19 | III, randomized, open-label, ENSURE study. Ann Oncol 2015; 26: 20 | 1883–9. 21 | } 22 | \usage{ 23 | ENSURE_3A 24 | } 25 | \description{ 26 | Kaplan-Meier digitized data from ENSURE, figure 3A (PMID 26105600). A reported sample size of 217 for a primary endpoint of PFS in lung cancer. 27 | } 28 | \examples{ 29 | summary(ENSURE_3A) 30 | 31 | kmplot(ENSURE_3A) 32 | } 33 | \keyword{datasets} 34 | -------------------------------------------------------------------------------- /man/ERCC1_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ERCC1_2A} 5 | \alias{ERCC1_2A} 6 | \title{ERCC1, figure 2A} 7 | \format{ 8 | A data frame of 464 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (cisplatin, p1) \cr 13 | } 14 | } 15 | \source{ 16 | Lee SM, Falzon M, Blackhall F, et al. Randomized Prospective 17 | Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum 18 | Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). J 19 | Clin Oncol 2017; 35: 402–11. 20 | } 21 | \usage{ 22 | ERCC1_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from ERCC1, figure 2A (PMID 27893326). A reported sample size of 648 for a primary endpoint of OS in lung cancer. 26 | } 27 | \examples{ 28 | summary(ERCC1_2A) 29 | 30 | kmplot(ERCC1_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/ERCC1_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ERCC1_2B} 5 | \alias{ERCC1_2B} 6 | \title{ERCC1, figure 2B} 7 | \format{ 8 | A data frame of 468 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (cisplatin_pemetrexed, p1) \cr 13 | } 14 | } 15 | \source{ 16 | Lee SM, Falzon M, Blackhall F, et al. Randomized Prospective 17 | Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum 18 | Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). J 19 | Clin Oncol 2017; 35: 402–11. 20 | } 21 | \usage{ 22 | ERCC1_2B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from ERCC1, figure 2B (PMID 27893326). A reported sample size of 648 for a primary endpoint of OS in lung cancer. 26 | } 27 | \examples{ 28 | summary(ERCC1_2B) 29 | 30 | kmplot(ERCC1_2B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/ERCC1_2C.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ERCC1_2C} 5 | \alias{ERCC1_2C} 6 | \title{ERCC1, figure 2C} 7 | \format{ 8 | A data frame of 168 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (cisplatin, paclitaxel_gemcitabine) \cr 13 | } 14 | } 15 | \source{ 16 | Lee SM, Falzon M, Blackhall F, et al. Randomized Prospective 17 | Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum 18 | Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). J 19 | Clin Oncol 2017; 35: 402–11. 20 | } 21 | \usage{ 22 | ERCC1_2C 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from ERCC1, figure 2C (PMID 27893326). A reported sample size of 648 for a primary endpoint of OS in lung cancer. 26 | } 27 | \examples{ 28 | summary(ERCC1_2C) 29 | 30 | kmplot(ERCC1_2C) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/ERCC1_2D.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ERCC1_2D} 5 | \alias{ERCC1_2D} 6 | \title{ERCC1, figure 2D} 7 | \format{ 8 | A data frame of 173 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (cisplatin, p1) \cr 13 | } 14 | } 15 | \source{ 16 | Lee SM, Falzon M, Blackhall F, et al. Randomized Prospective 17 | Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum 18 | Therapy in Advanced Non-Small-Cell Lung Cancer: ERCC1 Trial (ET). J 19 | Clin Oncol 2017; 35: 402–11. 20 | } 21 | \usage{ 22 | ERCC1_2D 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from ERCC1, figure 2D (PMID 27893326). A reported sample size of 648 for a primary endpoint of OS in lung cancer. 26 | } 27 | \examples{ 28 | summary(ERCC1_2D) 29 | 30 | kmplot(ERCC1_2D) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/FALCON_2.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{FALCON_2} 5 | \alias{FALCON_2} 6 | \title{FALCON, figure 2} 7 | \format{ 8 | A data frame of 462 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (anastrazole, fulvestrant) \cr 13 | } 14 | } 15 | \source{ 16 | Robertson JFR, Bondarenko IM, Trishkina E, et al. Fulvestrant 500 mg 17 | versus anastrozole 1 mg for hormone receptor-positive advanced breast 18 | cancer (FALCON): an international, randomised, double-blind, phase 3 19 | trial. Lancet 2016; 388: 2997–3005. 20 | } 21 | \usage{ 22 | FALCON_2 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from FALCON, figure 2 (PMID 27908454). A reported sample size of 462 for a primary endpoint of PFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(FALCON_2) 29 | 30 | kmplot(FALCON_2) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/FFCD2001_S1A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{FFCD2001_S1A} 5 | \alias{FFCD2001_S1A} 6 | \title{FFCD2001, figure S1A} 7 | \format{ 8 | A data frame of 282 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (fu, iri) \cr 13 | } 14 | } 15 | \source{ 16 | Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III 17 | trial in elderly patients comparing LV5FU2 with or without irinotecan 18 | for first-line treatment of metastatic colorectal cancer (FFCD 19 | 2001-02). Ann Oncol 2016; 27: 121–7. 20 | } 21 | \usage{ 22 | FFCD2001_S1A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from FFCD2001, figure S1A (PMID 26487578). A reported sample size of 212 for a primary endpoint of PFS in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(FFCD2001_S1A) 29 | 30 | kmplot(FFCD2001_S1A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/FFCD2001_S1B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{FFCD2001_S1B} 5 | \alias{FFCD2001_S1B} 6 | \title{FFCD2001, figure S1B} 7 | \format{ 8 | A data frame of 282 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (fu, iri) \cr 13 | } 14 | } 15 | \source{ 16 | Aparicio T, Lavau-Denes S, Phelip JM, et al. Randomized phase III 17 | trial in elderly patients comparing LV5FU2 with or without irinotecan 18 | for first-line treatment of metastatic colorectal cancer (FFCD 19 | 2001-02). Ann Oncol 2016; 27: 121–7. 20 | } 21 | \usage{ 22 | FFCD2001_S1B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from FFCD2001, figure S1B (PMID 26487578). A reported sample size of 212 for a primary endpoint of PFS in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(FFCD2001_S1B) 29 | 30 | kmplot(FFCD2001_S1B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/GIM2_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{GIM2_2A} 5 | \alias{GIM2_2A} 6 | \title{GIM2, figure 2A} 7 | \format{ 8 | A data frame of 2,091 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (ec_p, fec_p) \cr 13 | } 14 | } 15 | \source{ 16 | Del Mastro L, De Placido S, Bruzzi P, et al. Fluorouracil and 17 | dose-dense chemotherapy in adjuvant treatment of patients with 18 | early-stage breast cancer: an open-label, 2 × 2 factorial, randomised 19 | phase 3 trial. Lancet 2015; 385: 1863–72. 20 | } 21 | \usage{ 22 | GIM2_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from GIM2, figure 2A (PMID 25740286). A reported sample size of 2,091 for a primary endpoint of DFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(GIM2_2A) 29 | 30 | kmplot(GIM2_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/GIM2_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{GIM2_2B} 5 | \alias{GIM2_2B} 6 | \title{GIM2, figure 2B} 7 | \format{ 8 | A data frame of 2,091 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (ec_p, fec_p) \cr 13 | } 14 | } 15 | \source{ 16 | Del Mastro L, De Placido S, Bruzzi P, et al. Fluorouracil and 17 | dose-dense chemotherapy in adjuvant treatment of patients with 18 | early-stage breast cancer: an open-label, 2 × 2 factorial, randomised 19 | phase 3 trial. Lancet 2015; 385: 1863–72. 20 | } 21 | \usage{ 22 | GIM2_2B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from GIM2, figure 2B (PMID 25740286). A reported sample size of 2,091 for a primary endpoint of DFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(GIM2_2B) 29 | 30 | kmplot(GIM2_2B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/GIM2_2C.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{GIM2_2C} 5 | \alias{GIM2_2C} 6 | \title{GIM2, figure 2C} 7 | \format{ 8 | A data frame of 2,003 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (q2, q3) \cr 13 | } 14 | } 15 | \source{ 16 | Del Mastro L, De Placido S, Bruzzi P, et al. Fluorouracil and 17 | dose-dense chemotherapy in adjuvant treatment of patients with 18 | early-stage breast cancer: an open-label, 2 × 2 factorial, randomised 19 | phase 3 trial. Lancet 2015; 385: 1863–72. 20 | } 21 | \usage{ 22 | GIM2_2C 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from GIM2, figure 2C (PMID 25740286). A reported sample size of 2,091 for a primary endpoint of DFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(GIM2_2C) 29 | 30 | kmplot(GIM2_2C) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/GIM2_2D.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{GIM2_2D} 5 | \alias{GIM2_2D} 6 | \title{GIM2, figure 2D} 7 | \format{ 8 | A data frame of 2,003 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (q2, q3) \cr 13 | } 14 | } 15 | \source{ 16 | Del Mastro L, De Placido S, Bruzzi P, et al. Fluorouracil and 17 | dose-dense chemotherapy in adjuvant treatment of patients with 18 | early-stage breast cancer: an open-label, 2 × 2 factorial, randomised 19 | phase 3 trial. Lancet 2015; 385: 1863–72. 20 | } 21 | \usage{ 22 | GIM2_2D 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from GIM2, figure 2D (PMID 25740286). A reported sample size of 2,091 for a primary endpoint of DFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(GIM2_2D) 29 | 30 | kmplot(GIM2_2D) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/GIM_3.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{GIM_3} 5 | \alias{GIM_3} 6 | \title{GIM, figure 3} 7 | \format{ 8 | A data frame of 281 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (control, lhrha) \cr 13 | } 14 | } 15 | \source{ 16 | Lambertini M, Boni L, Michelotti A, et al. Ovarian Suppression With 17 | Triptorelin During Adjuvant Breast Cancer Chemotherapy and Long-term 18 | Ovarian Function, Pregnancies, and Disease-Free Survival: A 19 | Randomized Clinical Trial. JAMA 2015; 314: 2632–40. 20 | } 21 | \usage{ 22 | GIM_3 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from GIM, figure 3 (PMID 26720025). A reported sample size of 281 for a primary endpoint of Incidence_chemo-induced menopause in breast cancer. 26 | } 27 | \examples{ 28 | summary(GIM_3) 29 | 30 | kmplot(GIM_3) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/IBCSG2200_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{IBCSG2200_2A} 5 | \alias{IBCSG2200_2A} 6 | \title{IBCSG2200, figure 2A} 7 | \format{ 8 | A data frame of 1,081 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (cm, no cm) \cr 13 | } 14 | } 15 | \source{ 16 | Colleoni M, Gray KP, Gelber S, et al. Low-Dose Oral Cyclophosphamide 17 | and Methotrexate Maintenance for Hormone Receptor-Negative Early 18 | Breast Cancer: International Breast Cancer Study Group Trial 22-00. J 19 | Clin Oncol 2016; 34: 3400–8. 20 | } 21 | \usage{ 22 | IBCSG2200_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from IBCSG2200, figure 2A (PMID 27325862). A reported sample size of 1,086 for a primary endpoint of DFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(IBCSG2200_2A) 29 | 30 | kmplot(IBCSG2200_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/ITACa_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ITACa_2A} 5 | \alias{ITACa_2A} 6 | \title{ITACa, figure 2A} 7 | \format{ 8 | A data frame of 370 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (ct, ct_b) \cr 13 | } 14 | } 15 | \source{ 16 | Passardi A, Nanni O, Tassinari D, et al. Effectiveness of bevacizumab 17 | added to standard chemotherapy in metastatic colorectal cancer: final 18 | results for first-line treatment from the ITACa randomized clinical 19 | trial. Ann Oncol 2015; 26: 1201–7. 20 | } 21 | \usage{ 22 | ITACa_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from ITACa, figure 2A (PMID 25735317). A reported sample size of 376 for a primary endpoint of PFS in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(ITACa_2A) 29 | 30 | kmplot(ITACa_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/ITACa_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ITACa_2B} 5 | \alias{ITACa_2B} 6 | \title{ITACa, figure 2B} 7 | \format{ 8 | A data frame of 370 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (ct, ct_b) \cr 13 | } 14 | } 15 | \source{ 16 | Passardi A, Nanni O, Tassinari D, et al. Effectiveness of bevacizumab 17 | added to standard chemotherapy in metastatic colorectal cancer: final 18 | results for first-line treatment from the ITACa randomized clinical 19 | trial. Ann Oncol 2015; 26: 1201–7. 20 | } 21 | \usage{ 22 | ITACa_2B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from ITACa, figure 2B (PMID 25735317). A reported sample size of 376 for a primary endpoint of PFS in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(ITACa_2B) 29 | 30 | kmplot(ITACa_2B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/KEYNOTE024_1A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{KEYNOTE024_1A} 5 | \alias{KEYNOTE024_1A} 6 | \title{KEYNOTE024, figure 1A} 7 | \format{ 8 | A data frame of 305 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (chemo, pembrolizumab) \cr 13 | } 14 | } 15 | \source{ 16 | Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus 17 | Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J 18 | Med 2016; 375: 1823–33. 19 | } 20 | \usage{ 21 | KEYNOTE024_1A 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from KEYNOTE024, figure 1A (PMID 27718847). A reported sample size of 305 for a primary endpoint of PFS in lung cancer. 25 | } 26 | \examples{ 27 | summary(KEYNOTE024_1A) 28 | 29 | kmplot(KEYNOTE024_1A) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/KEYNOTE024_2.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{KEYNOTE024_2} 5 | \alias{KEYNOTE024_2} 6 | \title{KEYNOTE024, figure 2} 7 | \format{ 8 | A data frame of 305 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (chemo, pembrolizumab) \cr 13 | } 14 | } 15 | \source{ 16 | Reck M, Rodríguez-Abreu D, Robinson AG, et al. Pembrolizumab versus 17 | Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J 18 | Med 2016; 375: 1823–33. 19 | } 20 | \usage{ 21 | KEYNOTE024_2 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from KEYNOTE024, figure 2 (PMID 27718847). A reported sample size of 305 for a primary endpoint of PFS in lung cancer. 25 | } 26 | \examples{ 27 | summary(KEYNOTE024_2) 28 | 29 | kmplot(KEYNOTE024_2) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/LEA_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{LEA_2A} 5 | \alias{LEA_2A} 6 | \title{LEA, figure 2A} 7 | \format{ 8 | A data frame of 374 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (et, et_b) \cr 13 | } 14 | } 15 | \source{ 16 | Martín M, Loibl S, von Minckwitz G, et al. Phase III trial evaluating 17 | the addition of bevacizumab to endocrine therapy as first-line 18 | treatment for advanced breast cancer: the letrozole/fulvestrant and 19 | avastin (LEA) study. J Clin Oncol 2015; 33: 1045–52. 20 | } 21 | \usage{ 22 | LEA_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from LEA, figure 2A (PMID 25691671). A reported sample size of 374 for a primary endpoint of PFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(LEA_2A) 29 | 30 | kmplot(LEA_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/LEA_2C.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{LEA_2C} 5 | \alias{LEA_2C} 6 | \title{LEA, figure 2C} 7 | \format{ 8 | A data frame of 374 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (et, et_b) \cr 13 | } 14 | } 15 | \source{ 16 | Martín M, Loibl S, von Minckwitz G, et al. Phase III trial evaluating 17 | the addition of bevacizumab to endocrine therapy as first-line 18 | treatment for advanced breast cancer: the letrozole/fulvestrant and 19 | avastin (LEA) study. J Clin Oncol 2015; 33: 1045–52. 20 | } 21 | \usage{ 22 | LEA_2C 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from LEA, figure 2C (PMID 25691671). A reported sample size of 374 for a primary endpoint of PFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(LEA_2C) 29 | 30 | kmplot(LEA_2C) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/MA17R_1A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{MA17R_1A} 5 | \alias{MA17R_1A} 6 | \title{MA17R, figure 1A} 7 | \format{ 8 | A data frame of 1,918 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (l, placebo) \cr 13 | } 14 | } 15 | \source{ 16 | Goss PE, Ingle JN, Pritchard KI, et al. Extending Aromatase-Inhibitor 17 | Adjuvant Therapy to 10 Years. N Engl J Med 2016; 375: 209–19. 18 | } 19 | \usage{ 20 | MA17R_1A 21 | } 22 | \description{ 23 | Kaplan-Meier digitized data from MA17R, figure 1A (PMID 27264120). A reported sample size of 1,918 for a primary endpoint of DFS in breast cancer. 24 | } 25 | \examples{ 26 | summary(MA17R_1A) 27 | 28 | kmplot(MA17R_1A) 29 | } 30 | \keyword{datasets} 31 | -------------------------------------------------------------------------------- /man/MA17R_1B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{MA17R_1B} 5 | \alias{MA17R_1B} 6 | \title{MA17R, figure 1B} 7 | \format{ 8 | A data frame of 1,918 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (l, placebo) \cr 13 | } 14 | } 15 | \source{ 16 | Goss PE, Ingle JN, Pritchard KI, et al. Extending Aromatase-Inhibitor 17 | Adjuvant Therapy to 10 Years. N Engl J Med 2016; 375: 209–19. 18 | } 19 | \usage{ 20 | MA17R_1B 21 | } 22 | \description{ 23 | Kaplan-Meier digitized data from MA17R, figure 1B (PMID 27264120). A reported sample size of 1,918 for a primary endpoint of DFS in breast cancer. 24 | } 25 | \examples{ 26 | summary(MA17R_1B) 27 | 28 | kmplot(MA17R_1B) 29 | } 30 | \keyword{datasets} 31 | -------------------------------------------------------------------------------- /man/MA31_2.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{MA31_2} 5 | \alias{MA31_2} 6 | \title{MA31, figure 2} 7 | \format{ 8 | A data frame of 652 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (ltax_l, ttax_t) \cr 13 | } 14 | } 15 | \source{ 16 | Gelmon KA, Boyle FM, Kaufman B, et al. Lapatinib or Trastuzumab Plus 17 | Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive 18 | Advanced Breast Cancer: Final Results of NCIC CTG MA.31. J Clin Oncol 19 | 2015; 33: 1574–83. 20 | } 21 | \usage{ 22 | MA31_2 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from MA31, figure 2 (PMID 25779558). A reported sample size of 652 for a primary endpoint of PFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(MA31_2) 29 | 30 | kmplot(MA31_2) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/MA31_3.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{MA31_3} 5 | \alias{MA31_3} 6 | \title{MA31, figure 3} 7 | \format{ 8 | A data frame of 652 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (ltax_l, ttax_t) \cr 13 | } 14 | } 15 | \source{ 16 | Gelmon KA, Boyle FM, Kaufman B, et al. Lapatinib or Trastuzumab Plus 17 | Taxane Therapy for Human Epidermal Growth Factor Receptor 2-Positive 18 | Advanced Breast Cancer: Final Results of NCIC CTG MA.31. J Clin Oncol 19 | 2015; 33: 1574–83. 20 | } 21 | \usage{ 22 | MA31_3 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from MA31, figure 3 (PMID 25779558). A reported sample size of 652 for a primary endpoint of PFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(MA31_3) 29 | 30 | kmplot(MA31_3) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/MAPS_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{MAPS_2A} 5 | \alias{MAPS_2A} 6 | \title{MAPS, figure 2A} 7 | \format{ 8 | A data frame of 448 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (pc, pcb) \cr 13 | } 14 | } 15 | \source{ 16 | Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly 17 | diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin 18 | Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 19 | 3 trial. Lancet 2016; 387: 1405–14. 20 | } 21 | \usage{ 22 | MAPS_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from MAPS, figure 2A (PMID 26719230). A reported sample size of 448 for a primary endpoint of OS in lung cancer. 26 | } 27 | \examples{ 28 | summary(MAPS_2A) 29 | 30 | kmplot(MAPS_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/MAPS_2C.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{MAPS_2C} 5 | \alias{MAPS_2C} 6 | \title{MAPS, figure 2C} 7 | \format{ 8 | A data frame of 448 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (pc, pcb) \cr 13 | } 14 | } 15 | \source{ 16 | Zalcman G, Mazieres J, Margery J, et al. Bevacizumab for newly 17 | diagnosed pleural mesothelioma in the Mesothelioma Avastin Cisplatin 18 | Pemetrexed Study (MAPS): a randomised, controlled, open-label, phase 19 | 3 trial. Lancet 2016; 387: 1405–14. 20 | } 21 | \usage{ 22 | MAPS_2C 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from MAPS, figure 2C (PMID 26719230). A reported sample size of 448 for a primary endpoint of OS in lung cancer. 26 | } 27 | \examples{ 28 | summary(MAPS_2C) 29 | 30 | kmplot(MAPS_2C) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/MINDACT_2C.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{MINDACT_2C} 5 | \alias{MINDACT_2C} 6 | \title{MINDACT, figure 2C} 7 | \format{ 8 | A data frame of 1,497 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (chemo, no_chemotherapy) \cr 13 | } 14 | } 15 | \source{ 16 | Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene Signature as an 17 | Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 18 | 2016; 375: 717–29. 19 | } 20 | \usage{ 21 | MINDACT_2C 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from MINDACT, figure 2C (PMID 27557300). A reported sample size of 1,550 for a primary endpoint of DMFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(MINDACT_2C) 28 | 29 | kmplot(MINDACT_2C) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/MINDACT_2D.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{MINDACT_2D} 5 | \alias{MINDACT_2D} 6 | \title{MINDACT, figure 2D} 7 | \format{ 8 | A data frame of 690 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (chemo, no_chemotherapy) \cr 13 | } 14 | } 15 | \source{ 16 | Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene Signature as an 17 | Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 18 | 2016; 375: 717–29. 19 | } 20 | \usage{ 21 | MINDACT_2D 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from MINDACT, figure 2D (PMID 27557300). A reported sample size of 1,550 for a primary endpoint of DMFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(MINDACT_2D) 28 | 29 | kmplot(MINDACT_2D) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/MINDACT_2E.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{MINDACT_2E} 5 | \alias{MINDACT_2E} 6 | \title{MINDACT, figure 2E} 7 | \format{ 8 | A data frame of 690 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (chemo, no_chemotherapy) \cr 13 | } 14 | } 15 | \source{ 16 | Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene Signature as an 17 | Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 18 | 2016; 375: 717–29. 19 | } 20 | \usage{ 21 | MINDACT_2E 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from MINDACT, figure 2E (PMID 27557300). A reported sample size of 1,550 for a primary endpoint of DMFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(MINDACT_2E) 28 | 29 | kmplot(MINDACT_2E) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/MINDACT_2F.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{MINDACT_2F} 5 | \alias{MINDACT_2F} 6 | \title{MINDACT, figure 2F} 7 | \format{ 8 | A data frame of 690 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (chemo, no_chemotherapy) \cr 13 | } 14 | } 15 | \source{ 16 | Cardoso F, van’t Veer LJ, Bogaerts J, et al. 70-Gene Signature as an 17 | Aid to Treatment Decisions in Early-Stage Breast Cancer. N Engl J Med 18 | 2016; 375: 717–29. 19 | } 20 | \usage{ 21 | MINDACT_2F 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from MINDACT, figure 2F (PMID 27557300). A reported sample size of 1,550 for a primary endpoint of DMFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(MINDACT_2F) 28 | 29 | kmplot(MINDACT_2F) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/MONALEESA2_1.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{MONALEESA2_1} 5 | \alias{MONALEESA2_1} 6 | \title{MONALEESA2, figure 1} 7 | \format{ 8 | A data frame of 668 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (placebo, ribociclib_letrozole) \cr 13 | } 14 | } 15 | \source{ 16 | Hortobagyi GN, Stemmer SM, Burris HA, et al. Ribociclib as First-Line 17 | Therapy for HR-Positive, Advanced Breast Cancer. N Engl J Med 2016; 18 | 375: 1738–48. 19 | } 20 | \usage{ 21 | MONALEESA2_1 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from MONALEESA2, figure 1 (PMID 27717303). A reported sample size of 668 for a primary endpoint of PFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(MONALEESA2_1) 28 | 29 | kmplot(MONALEESA2_1) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/MRC-RT01_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{MRC-RT01_2A} 5 | \alias{MRC-RT01_2A} 6 | \title{MRC-RT01, figure 2A} 7 | \format{ 8 | A data frame of 836 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (control, escalated) \cr 13 | } 14 | } 15 | \source{ 16 | Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus 17 | control-dose conformal radiotherapy for prostate cancer: long-term 18 | results from the MRC RT01 randomised controlled trial. Lancet Oncol 19 | 2014; 15: 464–73. 20 | } 21 | \usage{ 22 | `MRC-RT01_2A` 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from MRC-RT01, figure 2A (PMID 24581940). A reported sample size of 862 for a primary endpoint of bPFS/OS in prostate cancer. 26 | } 27 | \examples{ 28 | summary(`MRC-RT01_2A`) 29 | 30 | kmplot(`MRC-RT01_2A`) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/MRC-RT01_2C.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{MRC-RT01_2C} 5 | \alias{MRC-RT01_2C} 6 | \title{MRC-RT01, figure 2C} 7 | \format{ 8 | A data frame of 835 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (control, escalated) \cr 13 | } 14 | } 15 | \source{ 16 | Dearnaley DP, Jovic G, Syndikus I, et al. Escalated-dose versus 17 | control-dose conformal radiotherapy for prostate cancer: long-term 18 | results from the MRC RT01 randomised controlled trial. Lancet Oncol 19 | 2014; 15: 464–73. 20 | } 21 | \usage{ 22 | `MRC-RT01_2C` 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from MRC-RT01, figure 2C (PMID 24581940). A reported sample size of 862 for a primary endpoint of bPFS/OS in prostate cancer. 26 | } 27 | \examples{ 28 | summary(`MRC-RT01_2C`) 29 | 30 | kmplot(`MRC-RT01_2C`) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/NCT00294996_1A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{NCT00294996_1A} 5 | \alias{NCT00294996_1A} 6 | \title{NCT00294996, figure 1A} 7 | \format{ 8 | A data frame of 363 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (mpt, pt) \cr 13 | } 14 | } 15 | \source{ 16 | Baselga J, Manikhas A, Cortés J, et al. Phase III trial of 17 | nonpegylated liposomal doxorubicin in combination with trastuzumab 18 | and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol 19 | 2014; 25: 592–8. 20 | } 21 | \usage{ 22 | NCT00294996_1A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from NCT00294996, figure 1A (PMID 24401928). A reported sample size of 181 for a primary endpoint of PFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(NCT00294996_1A) 29 | 30 | kmplot(NCT00294996_1A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/NCT00294996_1B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{NCT00294996_1B} 5 | \alias{NCT00294996_1B} 6 | \title{NCT00294996, figure 1B} 7 | \format{ 8 | A data frame of 363 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (mpt, pt) \cr 13 | } 14 | } 15 | \source{ 16 | Baselga J, Manikhas A, Cortés J, et al. Phase III trial of 17 | nonpegylated liposomal doxorubicin in combination with trastuzumab 18 | and paclitaxel in HER2-positive metastatic breast cancer. Ann Oncol 19 | 2014; 25: 592–8. 20 | } 21 | \usage{ 22 | NCT00294996_1B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from NCT00294996, figure 1B (PMID 24401928). A reported sample size of 181 for a primary endpoint of PFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(NCT00294996_1B) 29 | 30 | kmplot(NCT00294996_1B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/NCT01234311_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{NCT01234311_2A} 5 | \alias{NCT01234311_2A} 6 | \title{NCT01234311, figure 2A} 7 | \format{ 8 | A data frame of 577 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (placebo, tasq) \cr 13 | } 14 | } 15 | \source{ 16 | Sternberg C, Armstrong A, Pili R, et al. Randomized, Double-Blind, 17 | Placebo-Controlled Phase III Study of Tasquinimod in Men With 18 | Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 2016; 19 | 34: 2636–43. 20 | } 21 | \usage{ 22 | NCT01234311_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from NCT01234311, figure 2A (PMID 27298414). A reported sample size of 1,245 for a primary endpoint of rPFS in prostate cancer. 26 | } 27 | \examples{ 28 | summary(NCT01234311_2A) 29 | 30 | kmplot(NCT01234311_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/NCT01234311_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{NCT01234311_2B} 5 | \alias{NCT01234311_2B} 6 | \title{NCT01234311, figure 2B} 7 | \format{ 8 | A data frame of 1,158 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (placebo, tasq) \cr 13 | } 14 | } 15 | \source{ 16 | Sternberg C, Armstrong A, Pili R, et al. Randomized, Double-Blind, 17 | Placebo-Controlled Phase III Study of Tasquinimod in Men With 18 | Metastatic Castration-Resistant Prostate Cancer. J Clin Oncol 2016; 19 | 34: 2636–43. 20 | } 21 | \usage{ 22 | NCT01234311_2B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from NCT01234311, figure 2B (PMID 27298414). A reported sample size of 1,245 for a primary endpoint of rPFS in prostate cancer. 26 | } 27 | \examples{ 28 | summary(NCT01234311_2B) 29 | 30 | kmplot(NCT01234311_2B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/NITRO_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{NITRO_2A} 5 | \alias{NITRO_2A} 6 | \title{NITRO, figure 2A} 7 | \format{ 8 | A data frame of 372 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (chemo, nitro_chemo) \cr 13 | } 14 | } 15 | \source{ 16 | Davidson A, Veillard A-S, Tognela A, et al. A phase III randomized 17 | trial of adding topical nitroglycerin to first-line chemotherapy for 18 | advanced nonsmall-cell lung cancer: the Australasian lung cancer 19 | trials group NITRO trial. Ann Oncol 2015; 26: 2280–6. 20 | } 21 | \usage{ 22 | NITRO_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from NITRO, figure 2A (PMID 26347110). A reported sample size of 372 for a primary endpoint of PFS in lung cancer. 26 | } 27 | \examples{ 28 | summary(NITRO_2A) 29 | 30 | kmplot(NITRO_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/NITRO_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{NITRO_2B} 5 | \alias{NITRO_2B} 6 | \title{NITRO, figure 2B} 7 | \format{ 8 | A data frame of 372 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (chemo, nitro_chemo) \cr 13 | } 14 | } 15 | \source{ 16 | Davidson A, Veillard A-S, Tognela A, et al. A phase III randomized 17 | trial of adding topical nitroglycerin to first-line chemotherapy for 18 | advanced nonsmall-cell lung cancer: the Australasian lung cancer 19 | trials group NITRO trial. Ann Oncol 2015; 26: 2280–6. 20 | } 21 | \usage{ 22 | NITRO_2B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from NITRO, figure 2B (PMID 26347110). A reported sample size of 372 for a primary endpoint of PFS in lung cancer. 26 | } 27 | \examples{ 28 | summary(NITRO_2B) 29 | 30 | kmplot(NITRO_2B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/NSABPB40_3A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{NSABPB40_3A} 5 | \alias{NSABPB40_3A} 6 | \title{NSABPB40, figure 3A} 7 | \format{ 8 | A data frame of 1,184 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (bev, no_bev) \cr 13 | } 14 | } 15 | \source{ 16 | Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant 17 | bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): 18 | secondary outcomes of a phase 3, randomised controlled trial. Lancet 19 | Oncol 2015; 16: 1037–48. 20 | } 21 | \usage{ 22 | NSABPB40_3A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from NSABPB40, figure 3A (PMID 26272770). A reported sample size of 1,206 for a primary endpoint of pCR in breast cancer. 26 | } 27 | \examples{ 28 | summary(NSABPB40_3A) 29 | 30 | kmplot(NSABPB40_3A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/NSABPB40_3B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{NSABPB40_3B} 5 | \alias{NSABPB40_3B} 6 | \title{NSABPB40, figure 3B} 7 | \format{ 8 | A data frame of 1,186 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (bev, no_bev) \cr 13 | } 14 | } 15 | \source{ 16 | Bear HD, Tang G, Rastogi P, et al. Neoadjuvant plus adjuvant 17 | bevacizumab in early breast cancer (NSABP B-40 [NRG Oncology]): 18 | secondary outcomes of a phase 3, randomised controlled trial. Lancet 19 | Oncol 2015; 16: 1037–48. 20 | } 21 | \usage{ 22 | NSABPB40_3B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from NSABPB40, figure 3B (PMID 26272770). A reported sample size of 1,206 for a primary endpoint of pCR in breast cancer. 26 | } 27 | \examples{ 28 | summary(NSABPB40_3B) 29 | 30 | kmplot(NSABPB40_3B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/NTR1527_2.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{NTR1527_2} 5 | \alias{NTR1527_2} 6 | \title{NTR1527, figure 2} 7 | \format{ 8 | A data frame of 495 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (control, thoracic rt) \cr 13 | } 14 | } 15 | \source{ 16 | Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic 17 | radiotherapy for extensive stage small-cell lung cancer: a phase 3 18 | randomised controlled trial. Lancet 2015; 385: 36–42. 19 | } 20 | \usage{ 21 | NTR1527_2 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from NTR1527, figure 2 (PMID 25230595). A reported sample size of 498 for a primary endpoint of OS-1yr in lung cancer. 25 | } 26 | \examples{ 27 | summary(NTR1527_2) 28 | 29 | kmplot(NTR1527_2) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/NTR1527_4.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{NTR1527_4} 5 | \alias{NTR1527_4} 6 | \title{NTR1527, figure 4} 7 | \format{ 8 | A data frame of 495 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (control, thoracic rt) \cr 13 | } 14 | } 15 | \source{ 16 | Slotman BJ, van Tinteren H, Praag JO, et al. Use of thoracic 17 | radiotherapy for extensive stage small-cell lung cancer: a phase 3 18 | randomised controlled trial. Lancet 2015; 385: 36–42. 19 | } 20 | \usage{ 21 | NTR1527_4 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from NTR1527, figure 4 (PMID 25230595). A reported sample size of 498 for a primary endpoint of OS-1yr in lung cancer. 25 | } 26 | \examples{ 27 | summary(NTR1527_4) 28 | 29 | kmplot(NTR1527_4) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/PALOMA2_1A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{PALOMA2_1A} 5 | \alias{PALOMA2_1A} 6 | \title{PALOMA2, figure 1A} 7 | \format{ 8 | A data frame of 666 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (palbociclib_letrozole, placebo_letrozole) \cr 13 | } 14 | } 15 | \source{ 16 | Finn RS, Martin M, Rugo HS, et al. Palbociclib and Letrozole in 17 | Advanced Breast Cancer. N Engl J Med 2016; 375: 1925–36. 18 | } 19 | \usage{ 20 | PALOMA2_1A 21 | } 22 | \description{ 23 | Kaplan-Meier digitized data from PALOMA2, figure 1A (PMID 27959613). A reported sample size of 666 for a primary endpoint of PFS in breast cancer. 24 | } 25 | \examples{ 26 | summary(PALOMA2_1A) 27 | 28 | kmplot(PALOMA2_1A) 29 | } 30 | \keyword{datasets} 31 | -------------------------------------------------------------------------------- /man/PALOMA3_1A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{PALOMA3_1A} 5 | \alias{PALOMA3_1A} 6 | \title{PALOMA3, figure 1A} 7 | \format{ 8 | A data frame of 521 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (palbociclib_fulvestrant, placebo_fulvestrant) \cr 13 | } 14 | } 15 | \source{ 16 | Turner NC, Ro J, André F, et al. Palbociclib in 17 | Hormone-Receptor-Positive Advanced Breast Cancer. N Engl J Med 2015; 18 | 373: 209–19. 19 | } 20 | \usage{ 21 | PALOMA3_1A 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from PALOMA3, figure 1A (PMID 26030518). A reported sample size of 521 for a primary endpoint of PFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(PALOMA3_1A) 28 | 29 | kmplot(PALOMA3_1A) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/PREVAIL_1A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{PREVAIL_1A} 5 | \alias{PREVAIL_1A} 6 | \title{PREVAIL, figure 1A} 7 | \format{ 8 | A data frame of 1,633 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab RPFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (enzalutamide, placebo) \cr 13 | } 14 | } 15 | \source{ 16 | Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic 17 | prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424–33. 18 | } 19 | \usage{ 20 | PREVAIL_1A 21 | } 22 | \description{ 23 | Kaplan-Meier digitized data from PREVAIL, figure 1A (PMID 24881730). A reported sample size of 1,717 for a primary endpoint of PFS/OS in prostate cancer. 24 | } 25 | \examples{ 26 | summary(PREVAIL_1A) 27 | 28 | kmplot(PREVAIL_1A) 29 | } 30 | \keyword{datasets} 31 | -------------------------------------------------------------------------------- /man/PREVAIL_1B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{PREVAIL_1B} 5 | \alias{PREVAIL_1B} 6 | \title{PREVAIL, figure 1B} 7 | \format{ 8 | A data frame of 1,717 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (enzalutamide, placebo) \cr 13 | } 14 | } 15 | \source{ 16 | Beer TM, Armstrong AJ, Rathkopf DE, et al. Enzalutamide in metastatic 17 | prostate cancer before chemotherapy. N Engl J Med 2014; 371: 424–33. 18 | } 19 | \usage{ 20 | PREVAIL_1B 21 | } 22 | \description{ 23 | Kaplan-Meier digitized data from PREVAIL, figure 1B (PMID 24881730). A reported sample size of 1,717 for a primary endpoint of PFS/OS in prostate cancer. 24 | } 25 | \examples{ 26 | summary(PREVAIL_1B) 27 | 28 | kmplot(PREVAIL_1B) 29 | } 30 | \keyword{datasets} 31 | -------------------------------------------------------------------------------- /man/PROFILE1014_1A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{PROFILE1014_1A} 5 | \alias{PROFILE1014_1A} 6 | \title{PROFILE1014, figure 1A} 7 | \format{ 8 | A data frame of 343 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (chemo, crizotinib) \cr 13 | } 14 | } 15 | \source{ 16 | Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus 17 | chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 18 | 2167–77. 19 | } 20 | \usage{ 21 | PROFILE1014_1A 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from PROFILE1014, figure 1A (PMID 25470694). A reported sample size of 343 for a primary endpoint of PFS in lung cancer. 25 | } 26 | \examples{ 27 | summary(PROFILE1014_1A) 28 | 29 | kmplot(PROFILE1014_1A) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/PROFILE1014_1B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{PROFILE1014_1B} 5 | \alias{PROFILE1014_1B} 6 | \title{PROFILE1014, figure 1B} 7 | \format{ 8 | A data frame of 343 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (chemo, crizotinib) \cr 13 | } 14 | } 15 | \source{ 16 | Solomon BJ, Mok T, Kim D-W, et al. First-line crizotinib versus 17 | chemotherapy in ALK-positive lung cancer. N Engl J Med 2014; 371: 18 | 2167–77. 19 | } 20 | \usage{ 21 | PROFILE1014_1B 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from PROFILE1014, figure 1B (PMID 25470694). A reported sample size of 343 for a primary endpoint of PFS in lung cancer. 25 | } 26 | \examples{ 27 | summary(PROFILE1014_1B) 28 | 29 | kmplot(PROFILE1014_1B) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/QUASAR2_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{QUASAR2_2A} 5 | \alias{QUASAR2_2A} 6 | \title{QUASAR2, figure 2A} 7 | \format{ 8 | A data frame of 1,933 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (cap, cap_bev) \cr 13 | } 14 | } 15 | \source{ 16 | Kerr RS, Love S, Segelov E, et al. Adjuvant capecitabine plus 17 | bevacizumab versus capecitabine alone in patients with colorectal 18 | cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet 19 | Oncol 2016; 17: 1543–57. 20 | } 21 | \usage{ 22 | QUASAR2_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from QUASAR2, figure 2A (PMID 27660192). A reported sample size of 1,952 for a primary endpoint of DFS3 in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(QUASAR2_2A) 29 | 30 | kmplot(QUASAR2_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/QUASAR2_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{QUASAR2_2B} 5 | \alias{QUASAR2_2B} 6 | \title{QUASAR2, figure 2B} 7 | \format{ 8 | A data frame of 1,939 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (cap, cap_bev) \cr 13 | } 14 | } 15 | \source{ 16 | Kerr RS, Love S, Segelov E, et al. Adjuvant capecitabine plus 17 | bevacizumab versus capecitabine alone in patients with colorectal 18 | cancer (QUASAR 2): an open-label, randomised phase 3 trial. Lancet 19 | Oncol 2016; 17: 1543–57. 20 | } 21 | \usage{ 22 | QUASAR2_2B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from QUASAR2, figure 2B (PMID 27660192). A reported sample size of 1,952 for a primary endpoint of DFS3 in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(QUASAR2_2B) 29 | 30 | kmplot(QUASAR2_2B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/R98_2.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{R98_2} 5 | \alias{R98_2} 6 | \title{R98, figure 2} 7 | \format{ 8 | A data frame of 357 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (5fulv, 5fulv_cpt11) \cr 13 | } 14 | } 15 | \source{ 16 | Delbaldo C, Ychou M, Zawadi A, et al. Postoperative irinotecan in 17 | resected stage II-III rectal cancer: final analysis of the French R98 18 | Intergroup trial†. Ann Oncol 2015; 26: 1208–15. 19 | } 20 | \usage{ 21 | R98_2 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from R98, figure 2 (PMID 25739671). A reported sample size of 357 for a primary endpoint of DFS in colorectal cancer. 25 | } 26 | \examples{ 27 | summary(R98_2) 28 | 29 | kmplot(R98_2) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/R98_4.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{R98_4} 5 | \alias{R98_4} 6 | \title{R98, figure 4} 7 | \format{ 8 | A data frame of 357 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (5fulv, 5fulv_cpt11) \cr 13 | } 14 | } 15 | \source{ 16 | Delbaldo C, Ychou M, Zawadi A, et al. Postoperative irinotecan in 17 | resected stage II-III rectal cancer: final analysis of the French R98 18 | Intergroup trial†. Ann Oncol 2015; 26: 1208–15. 19 | } 20 | \usage{ 21 | R98_4 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from R98, figure 4 (PMID 25739671). A reported sample size of 357 for a primary endpoint of DFS in colorectal cancer. 25 | } 26 | \examples{ 27 | summary(R98_4) 28 | 29 | kmplot(R98_4) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/RADIANT_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{RADIANT_2A} 5 | \alias{RADIANT_2A} 6 | \title{RADIANT, figure 2A} 7 | \format{ 8 | A data frame of 973 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (erlotinib, placebo) \cr 13 | } 14 | } 15 | \source{ 16 | Kelly K, Altorki NK, Eberhardt WEE, et al. Adjuvant Erlotinib Versus 17 | Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer 18 | (RADIANT): A Randomized, Double-Blind, Phase III Trial. J Clin Oncol 19 | 2015; 33: 4007–14. 20 | } 21 | \usage{ 22 | RADIANT_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from RADIANT, figure 2A (PMID 26324372). A reported sample size of 973 for a primary endpoint of DFS in lung cancer. 26 | } 27 | \examples{ 28 | summary(RADIANT_2A) 29 | 30 | kmplot(RADIANT_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/RECOURSE_1A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{RECOURSE_1A} 5 | \alias{RECOURSE_1A} 6 | \title{RECOURSE, figure 1A} 7 | \format{ 8 | A data frame of 800 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (placebo, tas-102) \cr 13 | } 14 | } 15 | \source{ 16 | Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 17 | for refractory metastatic colorectal cancer. N Engl J Med 2015; 372: 18 | 1909–19. 19 | } 20 | \usage{ 21 | RECOURSE_1A 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from RECOURSE, figure 1A (PMID 25970050). A reported sample size of 800 for a primary endpoint of OS in breast cancer. 25 | } 26 | \examples{ 27 | summary(RECOURSE_1A) 28 | 29 | kmplot(RECOURSE_1A) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/RECOURSE_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{RECOURSE_2A} 5 | \alias{RECOURSE_2A} 6 | \title{RECOURSE, figure 2A} 7 | \format{ 8 | A data frame of 800 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (placebo, tas102) \cr 13 | } 14 | } 15 | \source{ 16 | Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 17 | for refractory metastatic colorectal cancer. N Engl J Med 2015; 372: 18 | 1909–19. 19 | } 20 | \usage{ 21 | RECOURSE_2A 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from RECOURSE, figure 2A (PMID 25970050). A reported sample size of 800 for a primary endpoint of OS in breast cancer. 25 | } 26 | \examples{ 27 | summary(RECOURSE_2A) 28 | 29 | kmplot(RECOURSE_2A) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/ROSE_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ROSE_2A} 5 | \alias{ROSE_2A} 6 | \title{ROSE, figure 2A} 7 | \format{ 8 | A data frame of 1,144 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (pbo_doc, ram_doc) \cr 13 | } 14 | } 15 | \source{ 16 | Mackey JR, Ramos-Vazquez M, Lipatov O, et al. Primary results of 17 | ROSE/TRIO-12, a randomized placebo-controlled phase III trial 18 | evaluating the addition of ramucirumab to first-line docetaxel 19 | chemotherapy in metastatic breast cancer. J Clin Oncol 2015; 33: 20 | 141–8. 21 | } 22 | \usage{ 23 | ROSE_2A 24 | } 25 | \description{ 26 | Kaplan-Meier digitized data from ROSE, figure 2A (PMID 25185099). A reported sample size of 1,144 for a primary endpoint of PFS in breast cancer. 27 | } 28 | \examples{ 29 | summary(ROSE_2A) 30 | 31 | kmplot(ROSE_2A) 32 | } 33 | \keyword{datasets} 34 | -------------------------------------------------------------------------------- /man/ROSE_2C.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{ROSE_2C} 5 | \alias{ROSE_2C} 6 | \title{ROSE, figure 2C} 7 | \format{ 8 | A data frame of 1,144 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (pbo_doc, ram_doc) \cr 13 | } 14 | } 15 | \source{ 16 | Mackey JR, Ramos-Vazquez M, Lipatov O, et al. Primary results of 17 | ROSE/TRIO-12, a randomized placebo-controlled phase III trial 18 | evaluating the addition of ramucirumab to first-line docetaxel 19 | chemotherapy in metastatic breast cancer. J Clin Oncol 2015; 33: 20 | 141–8. 21 | } 22 | \usage{ 23 | ROSE_2C 24 | } 25 | \description{ 26 | Kaplan-Meier digitized data from ROSE, figure 2C (PMID 25185099). A reported sample size of 1,144 for a primary endpoint of PFS in breast cancer. 27 | } 28 | \examples{ 29 | summary(ROSE_2C) 30 | 31 | kmplot(ROSE_2C) 32 | } 33 | \keyword{datasets} 34 | -------------------------------------------------------------------------------- /man/RTOG0415_2.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{RTOG0415_2} 5 | \alias{RTOG0415_2} 6 | \title{RTOG0415, figure 2} 7 | \format{ 8 | A data frame of 1,092 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (70gy, 73.8gy) \cr 13 | } 14 | } 15 | \source{ 16 | Lee WR, Dignam JJ, Amin MB, et al. Randomized Phase III 17 | Noninferiority Study Comparing Two Radiotherapy Fractionation 18 | Schedules in Patients With Low-Risk Prostate Cancer. J Clin Oncol 19 | 2016; 34: 2325–32. 20 | } 21 | \usage{ 22 | RTOG0415_2 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from RTOG0415, figure 2 (PMID 27044935). A reported sample size of 1,115 for a primary endpoint of DFS in prostate cancer. 26 | } 27 | \examples{ 28 | summary(RTOG0415_2) 29 | 30 | kmplot(RTOG0415_2) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/RTOG9804_2C.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{RTOG9804_2C} 5 | \alias{RTOG9804_2C} 6 | \title{RTOG9804, figure 2C} 7 | \format{ 8 | A data frame of 585 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (observation, rt) \cr 13 | } 14 | } 15 | \source{ 16 | McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective 17 | randomized trial for good-risk ductal carcinoma in situ comparing 18 | radiotherapy with observation. J Clin Oncol 2015; 33: 709–15. 19 | } 20 | \usage{ 21 | RTOG9804_2C 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from RTOG9804, figure 2C (PMID 25605856). A reported sample size of 632 for a primary endpoint of ILF in breast cancer. 25 | } 26 | \examples{ 27 | summary(RTOG9804_2C) 28 | 29 | kmplot(RTOG9804_2C) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/RTOG9804_2D.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{RTOG9804_2D} 5 | \alias{RTOG9804_2D} 6 | \title{RTOG9804, figure 2D} 7 | \format{ 8 | A data frame of 585 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (observation, rt) \cr 13 | } 14 | } 15 | \source{ 16 | McCormick B, Winter K, Hudis C, et al. RTOG 9804: a prospective 17 | randomized trial for good-risk ductal carcinoma in situ comparing 18 | radiotherapy with observation. J Clin Oncol 2015; 33: 709–15. 19 | } 20 | \usage{ 21 | RTOG9804_2D 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from RTOG9804, figure 2D (PMID 25605856). A reported sample size of 632 for a primary endpoint of ILF in breast cancer. 25 | } 26 | \examples{ 27 | summary(RTOG9804_2D) 28 | 29 | kmplot(RTOG9804_2D) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/SAKK_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{SAKK_2A} 5 | \alias{SAKK_2A} 6 | \title{SAKK, figure 2A} 7 | \format{ 8 | A data frame of 232 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab EFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (chemo_surgery, crt_surgery) \cr 13 | } 14 | } 15 | \source{ 16 | Pless M, Stupp R, Ris H-B, et al. Induction chemoradiation in stage 17 | IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. 18 | Lancet 2015; 386: 1049–56. 19 | } 20 | \usage{ 21 | SAKK_2A 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from SAKK, figure 2A (PMID 26275735). A reported sample size of 232 for a primary endpoint of EFS in lung cancer. 25 | } 26 | \examples{ 27 | summary(SAKK_2A) 28 | 29 | kmplot(SAKK_2A) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/SAKK_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{SAKK_2B} 5 | \alias{SAKK_2B} 6 | \title{SAKK, figure 2B} 7 | \format{ 8 | A data frame of 232 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (chemo_surgery, crt_surgery) \cr 13 | } 14 | } 15 | \source{ 16 | Pless M, Stupp R, Ris H-B, et al. Induction chemoradiation in stage 17 | IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. 18 | Lancet 2015; 386: 1049–56. 19 | } 20 | \usage{ 21 | SAKK_2B 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from SAKK, figure 2B (PMID 26275735). A reported sample size of 232 for a primary endpoint of EFS in lung cancer. 25 | } 26 | \examples{ 27 | summary(SAKK_2B) 28 | 29 | kmplot(SAKK_2B) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/SELECTBC_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{SELECTBC_2A} 5 | \alias{SELECTBC_2A} 6 | \title{SELECTBC, figure 2A} 7 | \format{ 8 | A data frame of 592 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (s_1, taxane) \cr 13 | } 14 | } 15 | \source{ 16 | Takashima T, Mukai H, Hara F, et al. Taxanes versus S-1 as the 17 | first-line chemotherapy for metastatic breast cancer (SELECT BC): an 18 | open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 19 | 2016; 17: 90–8. 20 | } 21 | \usage{ 22 | SELECTBC_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from SELECTBC, figure 2A (PMID 26617202). A reported sample size of 618 for a primary endpoint of OS in breast cancer. 26 | } 27 | \examples{ 28 | summary(SELECTBC_2A) 29 | 30 | kmplot(SELECTBC_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/SELECTBC_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{SELECTBC_2B} 5 | \alias{SELECTBC_2B} 6 | \title{SELECTBC, figure 2B} 7 | \format{ 8 | A data frame of 592 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab TTF event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (s1, taxane) \cr 13 | } 14 | } 15 | \source{ 16 | Takashima T, Mukai H, Hara F, et al. Taxanes versus S-1 as the 17 | first-line chemotherapy for metastatic breast cancer (SELECT BC): an 18 | open-label, non-inferiority, randomised phase 3 trial. Lancet Oncol 19 | 2016; 17: 90–8. 20 | } 21 | \usage{ 22 | SELECTBC_2B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from SELECTBC, figure 2B (PMID 26617202). A reported sample size of 618 for a primary endpoint of OS in breast cancer. 26 | } 27 | \examples{ 28 | summary(SELECTBC_2B) 29 | 30 | kmplot(SELECTBC_2B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/SOFT_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{SOFT_2A} 5 | \alias{SOFT_2A} 6 | \title{SOFT, figure 2A} 7 | \format{ 8 | A data frame of 2,033 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (tamoxifen, tamoxifen_os) \cr 13 | } 14 | } 15 | \source{ 16 | Francis PA, Regan MM, Fleming GF, et al. Adjuvant ovarian suppression 17 | in premenopausal breast cancer. N Engl J Med 2015; 372: 436–46. 18 | } 19 | \usage{ 20 | SOFT_2A 21 | } 22 | \description{ 23 | Kaplan-Meier digitized data from SOFT, figure 2A (PMID 25495490). A reported sample size of 3,066 for a primary endpoint of DFS in breast cancer. 24 | } 25 | \examples{ 26 | summary(SOFT_2A) 27 | 28 | kmplot(SOFT_2A) 29 | } 30 | \keyword{datasets} 31 | -------------------------------------------------------------------------------- /man/TCOG0701_1A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{TCOG0701_1A} 5 | \alias{TCOG0701_1A} 6 | \title{TCOG0701, figure 1A} 7 | \format{ 8 | A data frame of 596 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (docetaxel_cis, s1_cis) \cr 13 | } 14 | } 15 | \source{ 16 | Kubota K, Sakai H, Katakami N, et al. A randomized phase III trial of 17 | oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese 18 | patients with advanced non-small-cell lung cancer: TCOG0701 CATS 19 | trial. Ann Oncol 2015; 26: 1401–8. 20 | } 21 | \usage{ 22 | TCOG0701_1A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from TCOG0701, figure 1A (PMID 25908605). A reported sample size of 608 for a primary endpoint of OS in lung cancer. 26 | } 27 | \examples{ 28 | summary(TCOG0701_1A) 29 | 30 | kmplot(TCOG0701_1A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/TCOG0701_1B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{TCOG0701_1B} 5 | \alias{TCOG0701_1B} 6 | \title{TCOG0701, figure 1B} 7 | \format{ 8 | A data frame of 596 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (docetaxel_cis, s1_cis) \cr 13 | } 14 | } 15 | \source{ 16 | Kubota K, Sakai H, Katakami N, et al. A randomized phase III trial of 17 | oral S-1 plus cisplatin versus docetaxel plus cisplatin in Japanese 18 | patients with advanced non-small-cell lung cancer: TCOG0701 CATS 19 | trial. Ann Oncol 2015; 26: 1401–8. 20 | } 21 | \usage{ 22 | TCOG0701_1B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from TCOG0701, figure 1B (PMID 25908605). A reported sample size of 608 for a primary endpoint of OS in lung cancer. 26 | } 27 | \examples{ 28 | summary(TCOG0701_1B) 29 | 30 | kmplot(TCOG0701_1B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/TEXT-SOFT-open-paren-2-close-paren-_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{TEXT-SOFT(2)_2A} 5 | \alias{TEXT-SOFT(2)_2A} 6 | \title{TEXT-SOFT(2), figure 2A} 7 | \format{ 8 | A data frame of 4,690 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab DFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (exemestane_os, tamoxifen_os) \cr 13 | } 14 | } 15 | \source{ 16 | Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with 17 | ovarian suppression in premenopausal breast cancer. N Engl J Med 18 | 2014; 371: 107–18. 19 | } 20 | \usage{ 21 | `TEXT-SOFT(2)_2A` 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from TEXT-SOFT(2), figure 2A (PMID 24881463). A reported sample size of 4,690 for a primary endpoint of DFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(`TEXT-SOFT(2)_2A`) 28 | 29 | kmplot(`TEXT-SOFT(2)_2A`) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/TEXT-SOFT-open-paren-2-close-paren-_2D.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{TEXT-SOFT(2)_2D} 5 | \alias{TEXT-SOFT(2)_2D} 6 | \title{TEXT-SOFT(2), figure 2D} 7 | \format{ 8 | A data frame of 4,690 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in years) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (exemestane_os, tamoxifen_os) \cr 13 | } 14 | } 15 | \source{ 16 | Pagani O, Regan MM, Walley BA, et al. Adjuvant exemestane with 17 | ovarian suppression in premenopausal breast cancer. N Engl J Med 18 | 2014; 371: 107–18. 19 | } 20 | \usage{ 21 | `TEXT-SOFT(2)_2D` 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from TEXT-SOFT(2), figure 2D (PMID 24881463). A reported sample size of 4,690 for a primary endpoint of DFS in breast cancer. 25 | } 26 | \examples{ 27 | summary(`TEXT-SOFT(2)_2D`) 28 | 29 | kmplot(`TEXT-SOFT(2)_2D`) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/TRIBE-open-paren-2-close-paren-_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{TRIBE(2)_2A} 5 | \alias{TRIBE(2)_2A} 6 | \title{TRIBE(2), figure 2A} 7 | \format{ 8 | A data frame of 508 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (folfiri_bevacizumab, folfoxiri_bevacizumab) \cr 13 | } 14 | } 15 | \source{ 16 | Mayer RJ, Van Cutsem E, Falcone A, et al. Randomized trial of TAS-102 17 | for refractory metastatic colorectal cancer. N Engl J Med 2015; 372: 18 | 1909–19. 19 | } 20 | \usage{ 21 | `TRIBE(2)_2A` 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from TRIBE(2), figure 2A (PMID 25970050). A reported sample size of 508 for a primary endpoint of PFS in colorectal cancer. 25 | } 26 | \examples{ 27 | summary(`TRIBE(2)_2A`) 28 | 29 | kmplot(`TRIBE(2)_2A`) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/TRIBE-open-paren-2-close-paren-_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{TRIBE(2)_2B} 5 | \alias{TRIBE(2)_2B} 6 | \title{TRIBE(2), figure 2B} 7 | \format{ 8 | A data frame of 508 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (folfiri_bevacizumab, folfoxiri_bevacizumab) \cr 13 | } 14 | } 15 | \source{ 16 | Loupakis F, Cremolini C, Masi G, et al. Initial Therapy with 17 | FOLFOXIRI and Bevacizumab for Metastatic Colorectal Cancer. N Engl J 18 | Med 2014; 371: 1609-18. 19 | } 20 | \usage{ 21 | `TRIBE(2)_2B` 22 | } 23 | \description{ 24 | Kaplan-Meier digitized data from TRIBE(2), figure 2B (PMID 25337750). A reported sample size of 508 for a primary endpoint of PFS in colorectal cancer. 25 | } 26 | \examples{ 27 | summary(`TRIBE(2)_2B`) 28 | 29 | kmplot(`TRIBE(2)_2B`) 30 | } 31 | \keyword{datasets} 32 | -------------------------------------------------------------------------------- /man/WJOG5108L_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{WJOG5108L_2A} 5 | \alias{WJOG5108L_2A} 6 | \title{WJOG5108L, figure 2A} 7 | \format{ 8 | A data frame of 559 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (erlotinib, gefitinib) \cr 13 | } 14 | } 15 | \source{ 16 | Urata Y, Katakami N, Morita S, et al. Randomized Phase III Study 17 | Comparing Gefitinib With Erlotinib in Patients With Previously 18 | Treated Advanced Lung Adenocarcinoma: WJOG 5108L. J Clin Oncol 2016; 19 | 34: 3248–57. 20 | } 21 | \usage{ 22 | WJOG5108L_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from WJOG5108L, figure 2A (PMID 27022112). A reported sample size of 561 for a primary endpoint of PFS in lung cancer. 26 | } 27 | \examples{ 28 | summary(WJOG5108L_2A) 29 | 30 | kmplot(WJOG5108L_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/WJOG5108L_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{WJOG5108L_2B} 5 | \alias{WJOG5108L_2B} 6 | \title{WJOG5108L, figure 2B} 7 | \format{ 8 | A data frame of 559 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (erlotinib, gefitinib) \cr 13 | } 14 | } 15 | \source{ 16 | Urata Y, Katakami N, Morita S, et al. Randomized Phase III Study 17 | Comparing Gefitinib With Erlotinib in Patients With Previously 18 | Treated Advanced Lung Adenocarcinoma: WJOG 5108L. J Clin Oncol 2016; 19 | 34: 3248–57. 20 | } 21 | \usage{ 22 | WJOG5108L_2B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from WJOG5108L, figure 2B (PMID 27022112). A reported sample size of 561 for a primary endpoint of PFS in lung cancer. 26 | } 27 | \examples{ 28 | summary(WJOG5108L_2B) 29 | 30 | kmplot(WJOG5108L_2B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/WSG-ARA_3.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{WSG-ARA_3} 5 | \alias{WSG-ARA_3} 6 | \title{WSG-ARA, figure 3} 7 | \format{ 8 | A data frame of 1,170 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab EFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (da_negative, da_positive) \cr 13 | } 14 | } 15 | \source{ 16 | Nitz U, Gluz O, Zuna I, et al. Final results from the prospective 17 | phase III WSG-ARA trial: impact of adjuvant darbepoetin alfa on 18 | event-free survival in early breast cancer. Ann Oncol 2014; 25: 19 | 75–80. 20 | } 21 | \usage{ 22 | `WSG-ARA_3` 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from WSG-ARA, figure 3 (PMID 24356620). A reported sample size of 1,234 for a primary endpoint of EFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(`WSG-ARA_3`) 29 | 30 | kmplot(`WSG-ARA_3`) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/WSGAGO_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{WSGAGO_2A} 5 | \alias{WSGAGO_2A} 6 | \title{WSGAGO, figure 2A} 7 | \format{ 8 | A data frame of 1,930 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab EFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (control, ed_doc) \cr 13 | } 14 | } 15 | \source{ 16 | Nitz U, Gluz O, Huober J, et al. Final analysis of the prospective 17 | WSG-AGO EC-Doc versus FEC phase III trial in intermediate-risk (pN1) 18 | early breast cancer: efficacy and predictive value of Ki67 19 | expression. Ann Oncol 2014; 25: 1551–7. 20 | } 21 | \usage{ 22 | WSGAGO_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from WSGAGO, figure 2A (PMID 24827128). A reported sample size of 2,011 for a primary endpoint of EFS in breast cancer. 26 | } 27 | \examples{ 28 | summary(WSGAGO_2A) 29 | 30 | kmplot(WSGAGO_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/X20050181_1A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{X20050181_1A} 5 | \alias{X20050181_1A} 6 | \title{20050181, figure 1A} 7 | \format{ 8 | A data frame of 597 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (folfiri, panitumumab_folfiri) \cr 13 | } 14 | } 15 | \source{ 16 | Peeters M, Price TJ, Cervantes A, et al. Final results from a 17 | randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line 18 | treatment of metastatic colorectal cancer. Ann Oncol 2014; 25: 19 | 107–16. 20 | } 21 | \usage{ 22 | X20050181_1A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from 20050181, figure 1A (PMID 24356622). A reported sample size of 1,186 for a primary endpoint of PFS/OS in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(X20050181_1A) 29 | 30 | kmplot(X20050181_1A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/X20050181_1B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{X20050181_1B} 5 | \alias{X20050181_1B} 6 | \title{20050181, figure 1B} 7 | \format{ 8 | A data frame of 486 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab PFS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (folfiri, panitumumab_folfiri) \cr 13 | } 14 | } 15 | \source{ 16 | Peeters M, Price TJ, Cervantes A, et al. Final results from a 17 | randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line 18 | treatment of metastatic colorectal cancer. Ann Oncol 2014; 25: 19 | 107–16. 20 | } 21 | \usage{ 22 | X20050181_1B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from 20050181, figure 1B (PMID 24356622). A reported sample size of 1,186 for a primary endpoint of PFS/OS in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(X20050181_1B) 29 | 30 | kmplot(X20050181_1B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/X20050181_2A.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{X20050181_2A} 5 | \alias{X20050181_2A} 6 | \title{20050181, figure 2A} 7 | \format{ 8 | A data frame of 597 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (folfiri, panitumumab_folfiri) \cr 13 | } 14 | } 15 | \source{ 16 | Peeters M, Price TJ, Cervantes A, et al. Final results from a 17 | randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line 18 | treatment of metastatic colorectal cancer. Ann Oncol 2014; 25: 19 | 107–16. 20 | } 21 | \usage{ 22 | X20050181_2A 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from 20050181, figure 2A (PMID 24356622). A reported sample size of 1,186 for a primary endpoint of PFS/OS in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(X20050181_2A) 29 | 30 | kmplot(X20050181_2A) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/X20050181_2B.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/data.R 3 | \docType{data} 4 | \name{X20050181_2B} 5 | \alias{X20050181_2B} 6 | \title{20050181, figure 2B} 7 | \format{ 8 | A data frame of 486 observations and 3 variables: 9 | \tabular{lll}{ 10 | \tab \code{time} \tab event time (in months) \cr 11 | \tab \code{event} \tab OS event indicator (\code{0}: no event, \code{1}: event) \cr 12 | \tab \code{arm} \tab treatment arms (folfiri, panitumumab_folfiri) \cr 13 | } 14 | } 15 | \source{ 16 | Peeters M, Price TJ, Cervantes A, et al. Final results from a 17 | randomized phase 3 study of FOLFIRI {+/-} panitumumab for second-line 18 | treatment of metastatic colorectal cancer. Ann Oncol 2014; 25: 19 | 107–16. 20 | } 21 | \usage{ 22 | X20050181_2B 23 | } 24 | \description{ 25 | Kaplan-Meier digitized data from 20050181, figure 2B (PMID 24356622). A reported sample size of 1,186 for a primary endpoint of PFS/OS in colorectal cancer. 26 | } 27 | \examples{ 28 | summary(X20050181_2B) 29 | 30 | kmplot(X20050181_2B) 31 | } 32 | \keyword{datasets} 33 | -------------------------------------------------------------------------------- /man/kmm.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/kmm.R 3 | \name{kmm} 4 | \alias{kmm} 5 | \title{Kaplan-Meier metrics} 6 | \usage{ 7 | kmm(x, y, times = NULL) 8 | } 9 | \arguments{ 10 | \item{x, y}{\code{survfit} objects} 11 | 12 | \item{times}{times to evaluate survival} 13 | } 14 | \description{ 15 | Compute metrics between two \code{\link[survival]{survfit}} objects; see 16 | examples in \code{\link{kmm_legend}}. 17 | } 18 | -------------------------------------------------------------------------------- /man/summary.kmdata.Rd: -------------------------------------------------------------------------------- 1 | % Generated by roxygen2: do not edit by hand 2 | % Please edit documentation in R/utils.R 3 | \name{summary.kmdata} 4 | \alias{summary.kmdata} 5 | \title{Summarize \code{kmdata}} 6 | \usage{ 7 | \method{summary}{kmdata}(object, message = TRUE, ...) 8 | } 9 | \arguments{ 10 | \item{object}{an object of class \code{"kmdata"}} 11 | 12 | \item{message}{logical; if \code{TRUE} (default), a description of the 13 | study will be printed with the summary} 14 | 15 | \item{...}{ignored} 16 | } 17 | \description{ 18 | Print a summary of a \code{kmdata} object. 19 | } 20 | \examples{ 21 | summary(ATTENTION_2A) 22 | 23 | } 24 | --------------------------------------------------------------------------------